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1 Doping and sport 
 
1.1 Sport, doping and society 
Throughout history, sports have played a major role in many aspects of human societies. 
From ancient Greece to the modern times, sport has often been used as a means to 
influence diplomatic, social, and political relations between countries, to promote political 
ideals through propaganda, or to express national unity[1,2]. 
This close relationship between sport and society is explained in good part by the fact that 
humans have an innate sense of competition. Sport is able to suffice this need by providing 
an artificial competition (against their own limits, against other humans, or against nature), 
which is codified by rules that are in accordance with positive values and ethical principles 
such as fair play, friendship, team spirit, and hard work to obtain achievements[3]. In the 
words (that became the Olympic creed) of Pierre de Coubertin[4], father of the modern 
Olympic Games, the spirit of sport is summarized: 
“The important thing in the Olympic Games is not to win, but to take part; the important 
thing in Life is not triumph, but the struggle; the essential thing is not to have conquered but 
to have fought well. To spread these principles is to build up a strong and more valiant and, 
above all, more scrupulous and more generous humanity.” 
Doping is one of the most serious threats to these principles and in general to sport ethics, 
being a practice that affects the image of sport besides posing a serious risk to individual 
health. The use of performance enhancing drugs is in fact an illegal shortcut athletes use to 
reach success in sport, that provide to an athlete an unfair advantage relative to a "clean" 
competitor[5].  
1.2 Brief history of modern doping and anti-doping 
Since the antiquity, the use of performance-enhancing agents by athletes (but also soldiers 
and gladiators) is documented. These substances consisted of preparations made from 
natural sources, such as herbs and fungi, containing for example caffeine, or strychnine[6]. 
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The first documented case of doping in the modern Olympic Games involves Thomas Hicks, 
the winner of the Helsinki 1904 marathon competition, who reportedly used strychnine and 
brandy during the race[7]. 
Advances in pharmaceutical research and production in the 20th century led to the 
development of synthetic chemicals and hormones. These drugs were designed with specific 
therapeutic indications; nevertheless, several of them were soon recognized by the athletes 
as a powerful way to boost their performances. 
Starting from the 1930s, amphetamines began to replace “natural” stimulants such as 
strychnine. These drugs were used to suppress feelings of fatigue, mainly in endurance 
sports such as cyclism. Stimulants have been used for years regardless of the health-related 
risk. The deaths of the Danish cyclist Knud Enemark Jensen at the Rome Olympic Games 
(1960) and of the British Tom Simpson at the Tour de France (1967) were linked to rumored 
stimulant abuse, though not confirmed[6,7].  
In 1967, the International Olympic Committee (IOC), triggered by these alarming events, 
instituted a Medical Commission to set up its first (short) list of prohibited substances. Over 
the years, new doping substances became available, and therefore the list of prohibited 
compounds was continuously updated[8,9].  
In the following years, other federations such as International Association of Athletic 
Federations (IAAF) and International Cycling Union (UCI) followed IOC with establishing their 
own anti-doping rules and introducing drug testing procedures. In 1968, drug tests were 
performed for the first time at the Winter Olympic Games in Grenoble and at the Summer 
Olympic Games in Mexico[9]. 
In the 1950s and 1960s, following amphetamines, the use of anabolic steroids became 
widespread. In the 1952 Olympics in Helsinki, the weightlifters from Soviet Olympic team 
first used testosterone to increase strength and power. In the 1960s, East Germany started a 
systematic doping program of performance enhancement to their athletes that would last 
until the end of the Cold War and the reunification of Germany. These treatments led to 
numerous gold medals, but also to severe physical and psychological changes in the athletes, 
due to the consequences of androgen administration[10,11].  
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Reliable test methods for the detection of anabolic androgenic steroids (AAS) were 
introduced in 1974. Meanwhile, new synthetic analogues of testosterone (synthetic steroids) 
became available on the market and were at the same time very attractive to athletes to 
improve their performances. Due to the large misuse of these substances, the IOC added 
AASs to its list of prohibited substances in 1967[12]. 
In the beginning of the 1980s, sport drug testing made an important step forward with the 
introduction of gas chromatography coupled to mass spectrometry, which provided more 
effective analyses[13]. The first GC-MS screening methods were successfully implemented at 
the 1983 Pan American Games and then in 1984 Olympic Games in Los Angeles. One of the 
most famous cases of doping occurred in 1988 Olympic Games in Seoul, when the detection 
of stanozolol by GC-MS led to the disqualification of sprinter Ben Johnson and the loss of his 
gold medal[14]. Nowadays, GC-MS is still the primary method of choice for AASs and together 
with liquid chromatography-mass spectrometry (LC-MS) represents the most used standard 
techniques in doping analysis[15]. 
Besides stimulants and AAS, other drugs found their way into sport and therefore were 
prohibited[16]. Narcotics can be used to reduce pain in particular sport (e.g.: combat sports) 
and have been prohibited since 1967. Glucocorticoids, which allow better performance in 
endurance sports competitions suppressing pain and inflammation, were banned in 2004. 
Cannabinoids (natural and synthetic) are prohibited since 1989 for their relaxing effect that 
can produce an indirect advantage to the athlete, and the risks associated to their use in 
some sports (e.g.: driving sports), and their use is regarded as being in contradiction with the 
spirit and the image of sport. Beta-blockers, able to reduce heart rate and thus blood 
pressure, were suspected to be used in those sport were calmness and control of the 
movements are required (e. g.: archery, shooting sports)[16]. 
Diuretics, on the other hand, were not used to enhance performance but were considered 
“masking agents” that could be used to dilute the presence of illegal substances and aid their 
excretion, impairing their detection. They can also be used to excrete water for rapid weight 
loss (relevant for some sport with weight categories such as boxing)[17]. Both beta-blockers 
and diuretics were banned in 1985.  Since 1993, beta-2 agonists are prohibited as well 
because of their stimulating and/or anabolic effects[18].  
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A more recent class of doping substances is represented by hormone antagonists and 
modulators, mainly with antiestrogenic activity, which increase indirectly testosterone 
production by altering biosynthetic pathways and hormone-receptor interactions. Metabolic 
modulators such as peroxisome proliferator-activated receptor delta (PPARδ) agonists (e.g. 
GW-1516), AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are also 
prohibited[19]. 
All the classes mentioned so far consist of small molecule drugs which are currently 
monitored by anti-doping laboratories by using multi-analyte GC-MS and LC-MS methods, 
capable to screen simultaneously for hundreds of compounds from different classes[15,20–22]. 
These methods have become increasingly effective over the years, taking advantage of new 
available technologies and progress in research[23–25]. Other substances and methods have 
emerged during the years which required new approaches and development of new, 
dedicated methodologies[26]. 
Peptide hormones made their appearance in the 1980s, taking advantage of newly 
introduced recombinant technologies, and were prohibited in 1989[27]. Recombinant 
erythropoietin (EPO), an erythropoiesis-stimulating agent, and growth hormone (hGH) were 
already available in the 1980s and are still among the most abused doping agents. Detection 
of their misuse represents a major front in the anti-doping war[6,10,28]. In recent years, the list 
of prohibited peptide hormones has grown exponentially. Peptide hormones, particularly 
“small” peptides (molecular weight < 2 kDa) represent one of the main objects of this 
thesis[29]. 
Blood doping, defined as "the administration of blood or blood-related products in order to 
increase the number of red blood cells in the body”, started to be used in the 1970s. Except 
for anecdotal evidences, the first known case of blood doping was in fact recorded in 1980 
Summer Olympics in Moscow in the 5 and 10 kilometer track races. Five years later, blood 
doping was officially banned[30,31]. An historical view of the use of doping substances is 
provided in Figure 1.1 
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Figure 1.1 Historical view of the (estimated) use of doping substances and methods over 
the decades, their prohibition from IOC/WADA and the implementation of detection 
methods. 
As the complexity of the doping phenomenon grew significantly during the decades (also as 
a matter of public health), it became necessary to obtain harmonization and standardization 
on the fight against doping in sport. 
After a major doping scandal during the 1998 Tour de France, a World Conference on Doping 
was organized in 1999 with the participation of the IOC, Governments, Federations and 
Institutions. The main result of this conference was the establishment of the World Anti-
Doping Agency (WADA), an independent organization with the aim of coordinating the fight 
against doping[32]. 
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2 World Anti-Doping Agency (WADA) 
 
Since its establishment, WADA has had the purpose to ensure a harmonized approach to 
anti-doping in all sports and all countries through developments of protocols and guidelines, 
collaboration with Law Enforcement, coordination of anti-doping activities, and promoting 
research, doping prevention and education. 
One of the most significant achievements has been the implementation of a harmonized set 
of anti-doping rules, the World Anti-Doping Code (Code)[33,34]. 
As stated in the Code, the purposes of the World Anti-Doping Code and the World Anti-
Doping Program which supports it are:  
 To protect the Athletes' fundamental right to participate in doping-free sport and thus 
promote health, fairness and equality for Athletes worldwide, and 
 To ensure harmonized, coordinated and effective anti-doping programs at the 
international and national level with regard to detection, deterrence and prevention of 
doping. 
Furthermore, WADA published since 2004 the List of Prohibited Substances and Methods 
(List), which, as the name suggests, includes all the drugs and the doping procedures which 
are not allowed in sport (Table 1.1)[35].   
A substance or a method can be included in the List in case two of the following conditions 
are fulfilled: 
 Medical or other scientific evidence, pharmacological effect or experience that the 
substance or method, alone or in combination with other substances or methods, has the 
potential to enhance or enhances sport performance; 
 To protect the Athletes' fundamental right to participate in doping-free sport and thus 
promote health, fairness and equality for Athletes worldwide, and 
 Medical or other scientific evidence, pharmacological effect or experience that the use of 
the substance or method represents an actual or potential health risk to the Athlete; 
 WADA's determination that the Use of the substance or method violates the 
 spirit of sport described in the Introduction to the Code. 
 17 
 
Since 2004, WADA is responsible for accrediting Anti-Doping laboratories that apply 
analytical methods and processes to provide evidentiary data for the monitoring of 
prohibited substances and methods[36]. 
 
Table 1.1 Categories of prohibited substances and methods in the 2014 List 
 
 
 
 
3 WADA accredited laboratories 
 
Currently, there are 32 WADA accredited laboratories around the world[37]. These structures 
have the essential role of performing doping control analyses. Furthermore, the laboratories 
are also carrying research programs of utmost importance for the constant improvement of 
drug testing methods. Doping control tests can be performed only by WADA accredited 
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laboratories. In order to achieve and maintain WADA accreditation, a laboratory must fulfill 
the criteria specified by the International Standard for Laboratories (ISL) and its related 
Technical Documents[36]. 
3.1 Analytical strategies in doping control laboratories 
Doping control analyses are generally performed in urine, a matrix that provides a prolonged 
detection time window, and less often in other matrices (blood, plasma, serum, hair…). 
The analysis of a doping sample begins with an initial testing procedure (screening). A 
screening analysis consists generally of a multi-analyte method that is used to detect 
suspicious or abnormal samples for more detailed analysis[36]. 
A good screening method must: 
 be able to identify a high number of different substances, or different classes in a 
single analysis (cost effectiveness) 
 guarantee detection of any compound at half the concentration of the established 
minimum required performance limit (MRPL) 
 have a high sample throughput and robustness 
 not generate any false negative results 
 minimize the number of false positive results 
Numerous works have been published during the years on GC-MS and LC-MS screening 
analysis. The trend described by these publications shows how laboratories have moved 
from multi-analyte, single-class[38,39] to multi-analyte, multi-class methods[23,24]. However, 
some substances or methods (e.g.: hGH, blood doping…) still require dedicated procedures. 
Once a suspicious sample has been identified, a confirmatory analysis is requested. With few 
exceptions, confirmation methods are also mainly based on GC-MS and LC-MS techniques, 
as also recommended by the WADA International Standard for Laboratories[36]. 
The use of the prohibited compound is confirmed when the analytical data fulfills the criteria 
given by WADA in comparison to the positive control sample. In this case, the laboratory 
must report the Adverse Analytical Finding (AAF). In the case of an AAF, the laboratory will 
inform the testing authority (TA). The TA will connect the result with the athlete on the basis 
of the sample code[36]. 
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In the last years, a major step forward in the fight against doping has been made with the 
introduction of the Athlete Biological Passport (ABP). The ABP is generated by 
measurements of different biological parameters that are influenced by use of doping agents 
through the time and for each athlete[40]. 
Currently, the ABP consists of the ‘Hematological Module’, introduced in 2009 for the 
detection of blood doping[41], and Steroidal Module, approved since January 2014, to detect 
steroid doping[42]. 
 
4 Peptide hormones and doping 
 
Peptides and proteins consist of chains of amino acids (AA) linked through amide (peptidic) 
bond. An arbitrary distinction based on the number of AA is made between peptides (2-50 
AA) and proteins (> 50 AA) (Figure 1.2). 
 
Figure 1.2 Examples of a short peptide (arginine vasopressin – source: 
http://www.chemicalbook.com/) and a bigger protein (human growth hormone – source: 
http://en.wikipedia.org/) 
Peptide hormones are biochemical compounds synthesized by glands and then secreted to 
control body physiology and behavior. Together with monoamines (e.g. adrenaline) and 
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lipid-derived hormones (e.g. steroids), peptide hormones are the three main chemical 
classes of hormones in human and, in general, in vertebrates[43]. 
Similarly to what happened to monoamines (stimulants) and lipid hormones (AAS), 
analogues of peptides have been developed by the pharmaceutical industry to mimic 
naturally occurring protein hormones for therapeutic purposes, particularly when 
recombinant technologies became available (Figure 1.3). In 2013, there were around 60-70 
approved peptide drugs in the global market, with 100-200 more in clinical trials, 400-600 
more in pre-clinical studies[44]. Likewise, an increasing number of peptide hormones has 
entered in the doping arena. 
 
Figure 1.3 Number of approved peptidic drugs per year over the decades. 
4.1 Classification by WADA 
Peptide hormones are classified in the 2015 WADA Prohibited List under section S2[35]: 
“S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS” 
The following substances, and other substances with similar chemical structure or similar 
biological effect(s), are prohibited: 
1. Erythropoietin-Receptor agonists: 
1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. darbepoietin (dEPO); 
erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and 
peginesatide; and methoxy polyethylene glycol-epoetin beta (CERA); 
1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290, asialo EPO and 
carbamylated EPO; 
 21 
 
2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. 
argon, xenon; 
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, 
e.g. buserelin, gonadorelin and triptorelin, in males; 
4. Corticotrophins and their releasing factors, e.g corticorelin; 
5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing 
Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth 
Hormone Secretagogues (GHS), e.g. ghrelin 
and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH-Releasing Peptides (GHRPs), 
e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2). 
Additional prohibited growth factors: 
Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth 
Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived 
Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth 
factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, 
energy utilization, regenerative capacity or fibre type switching. 
Regardless of the pharmacological/doping effect, the use of an unapproved substance 
(including peptide hormones) is prohibited according to the section S0: 
S0. NON-APPROVED SUBSTANCES  
Any pharmacological substance which is not addressed by any of the subsequent sections of 
the List and with no current approval by any governmental regulatory health authority for 
human therapeutic use (e.g.: drugs under pre-clinical or clinical development or discontinued, 
designer drugs, substances approved only for veterinary use) is prohibited at all times.  
As extensively discussed further in this study, the misuse of non-approved formulations 
containing peptide hormones has represented an emerging and already relevant 
phenomenon in the recent years. 
Furthermore, the peptide desmopressin is banned as an example of masking agent for blood 
doping (Section S5. DIURETICS AND OTHER MASKING AGENTS). 
4.2 Doping control analysis of peptide hormones: “size-
dependent” approaches 
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Detection of peptide hormones is currently one of the most challenging fronts in the fight 
against doping[26,27,45]. As evident in the definition present in the WADA List, the term 
“peptide hormones” includes numerous compounds with high diversity in terms of size and 
pharmacological properties. 
As a consequence of this variety, it is difficult to analyze simultaneously different substances 
or different classes of substances, unlike for small molecules. Therefore, whereas for classic, 
small molecules multi-analyte screening methods are well established and allow screening 
simultaneously for hundreds of compounds, analytical methods for peptides consist 
essentially of single- or oligoanalyte methods[46,47]. In this latter case, all the compounds 
usually belong to the same class. 
Besides the limitations related to the large array of prohibited peptide hormones, several 
other factors concur to make peptide hormone testing a complicated task: 
 Elevated similarity of some of the substances (e.g. EPO, hGH) to their endogenous 
analogues (more difficult to find a marker of misuse); indirect methods (ABP) may be 
necessary 
 Short half-life/detection window compared to non-peptidic drugs (hours vs. days) 
 Relatively high chemical instability, particularly if methionine (oxidation), asparagine 
or glutamine (deamidation) are present 
 Low plasma/urine concentrations (nano-, femtomole range) 
 More critical sample preparation than for small molecules: non-specific adsorption 
on surfaces, variable recovery, loss of analyte during transfer and drying steps can 
cause poor or irreproducible results 
 Unfavorable mass spectrometry behavior (mass spectrometry is the most used 
detection technique in sport drug testing: MS signal generally decreases with the 
mass of the intact protein)[48] 
 Lack of reference standards material 
However, a continuous, big effort has been put by anti-doping laboratories in the 
development of methods over the last decades, resulting in the development of sensitive 
and reliable methods for detection of peptide hormones. The development and continuous 
improvements of the methods for EPO and hGH[49] are a clear example. Despite representing 
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only a minor percentage (< 5%) of the total, the number of AAF related to misuse of peptide 
hormones is following a growing trend[50], also due to the improvements achieved in 
detection techniques (Figure 1.4). 
 
Figure 1.4 Number of AAF related to peptide misuse. (*)2005 statistics included also hCG 
AAFs in women. 
In recent years, numerous other peptide hormones have reached the focus of being misused 
for their performance-enhancing properties. Similarly, several detection methods have been 
published. These analytical methods can be roughly divided into two categories: 
 MS-based methods[51,52] 
 Immunoassays[53–55] 
As already mentioned, mass spectrometry is the preferred technique in doping control 
analysis. Compared to immunoassays such as enzyme-linked immunosorbent assay (ELISA), 
mass spectrometry provides more adequate selectivity for sport drug testing, being much 
less likely affected by cross-reactivity with metabolites and other substances other than the 
target analyte. Over the last years mass spectrometry has emerged as a valid tool for the 
analysis of peptides also in other fields, particular in clinical analysis for discovery of 
biomarkers[20,56–58]. 
Several works concerning LC-MS detection/determination of prohibited peptide hormones 
have been published in the last decade. These methods can be grouped according to the 
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sample preparation strategy: solid-phase extraction (SPE)[51] and immunoaffinity purification 
(IAP)[52]. 
Among the advantage of using SPE: 
 Cost effectiveness: SPE cartridges are much less expensive than antibodies and 
related tools (e.g. immunomagnetic beads or immunoaffinity columns) 
 Possibility to analyze numerous peptides from different classes: selectivity of 
purification does not depend on antigen-antibody interaction 
 generally easily expandable to detect new emerging peptides 
Among those of using IAP: 
 High specificity for the analyte, which reflects in extremely clean extracts, better 
quality of the MS signal (virtually no ion suppression) and provides confidence in the 
analytical results 
 Gentle conditions: organic solvents or strong acids/bases are not used 
 Time effective: no evaporation step needed 
As already mentioned, detectability of peptides becomes more difficult with increasing size. 
For peptides with a molecular weight > 2-3 kDa, almost all analytical methods described in 
literature involve the use of IAP. Due to the higher complexity and instability of the molecule 
and the general mass-dependent loss of MS sensitivity, the high purity of the injected 
samples and the gentle sample handling become utmost important to obtain sensitive and 
reliable methods.   
However, for bigger proteins such as hGH or EPO-related substances, mass spectrometry 
currently seems to lack sensitivity to detect the presence of the substance or provide a 
quantification. For example, hGH doping can currently be detected by the so-called “isoform 
differential immunoassay” and through determination of indirect serum markers[55]. 
Detection of EPO is based on isoelectric focusing (IEF)[53]. Human chorionic gonadotropin 
(hCG) misuse is also monitored by immunoassays[54]. Methods based on mass spectrometric 
detection of IGF-1, EPOs and hCG have been developed with promising results but their 
suitability for doping control still has to be determined[46,56]. Figure 1.5 summarizes this 
classification. 
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Figure 1.5 Scheme of the size-dependent classification of peptide hormones and the 
analytical techniques used for their detection. 
4.3 Small peptide hormones 
There are several major categories of prohibited peptide hormones and the compounds vary 
greatly in size, effects, and mechanism of action. This study focused mainly on the 
development of analytical methods for the detection of small (< 1.5-2 kDa) peptides, though 
in the context of black market of peptide hormones (see Part III), peptides of bigger size are 
described. 
Overall, the peptides investigated in this study can be grouped in four classes, based on their 
mode of action and pharmacological/doping/masking effect: 
1) Luteinizing hormone-releasing hormone (LHRH) agonists 
Synthetic derivatives of the decapeptide LHRH, designed to improve the pharmacokinetic 
properties of the endogenous peptide, activate the LHRH receptor resulting in increased 
secretion of follicle-stimulating hormone (FSH) and luteinzing hormone (LH). This class of 
drugs was originally developed for treatment of several conditions, including prostate 
cancer, estrogen-related disorders and gender identity related disorders. However, since 
intermittent application of GnRH agonists increases plasma testosterone concentrations, 
these drugs have gained relevance also in doping controls[59–61]. 
 26 
 
2) Growth-promoting hormones acting on the growth hormone/insulin-like growth factor 1 
(GH/IGF-1) axis 
IGF-1 is a potent anabolic hormone, mainly secreted by the liver after stimulation by GH. 
Synthesis and release of GH from the pituitary gland is regulated positively by the growth 
hormone-releasing hormone (GHRH) and negatively by somatostatin, both secreted by 
the hypothalamus. GH/IGF-1 axis-related peptidic drugs are generally used for diagnosis 
and treatment of GH deficiency and related disorders[62]. 
It is easy to imagine how this class of compounds can be attractive to cheating athletes. 
In fact, numerous peptidic doping agents acting at different points of the GH/IGF-1 axis 
have been described[63]. Limiting the list to those included in this study (and thus not 
including many others such as recombinant GH and IGF-1), the following sub-classes are 
described: 
 Growth hormone-releasing hormone (GHRH) analogues: synthetic derivatives of the 
hypothalamic 44-AA hormone that similarly increase GH production[64,65] 
 Growth hormone-releasing peptides (GHRPs): synthetic, non-natural oligopeptides 
that stimulate GH secretion but have no homology with GHRH[64,65] 
 Mechano-growth factors (MGFs): analogues of human MGF, a 28-AA, splice variant of 
IGF-1 produced in the liver that induce muscle growth and hypertrophy in case of 
mechanical stimulation or damage[66] 
 IGF-1 and analogues 
 GH fragments, particularly fragment 176-191 of GH, a portion of the molecule with 
lipolytic effects[67] 
3) Arginine vasopressin (AVP) analogues 
AVP, also known as antidiuretic hormone (ADH), is a cyclic nonapeptide that regulates 
body water retention by increasing water reabsorption in the kidney nephron [62]. AVP 
analogues, particularly its long-acting synthetic analogue desmopressin are used mainly 
for treatment of nocturnal enuresis, coagulation disorders and diabetes insipidus[68]. Due 
to the fact that AVP analogues can cause hemodilution, they can act as masking agents 
by altering the values of hematological parameters used to detect blood doping in the 
framework of the ABP[69] 
4) Thymosin beta-4 (Tβ4)fragments 
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The fragment 17-23, responsible for the actin-sequestring activity of the 43-AA peptide 
Tβ4[70], is currently not approved for any therapeutic application and it is illegally traded 
under the name TB-500. Due to its potential role in muscular and connective tissue 
regeneration, an use for similar purposes to those of MGFs can be hypothesized.  
As in the case of TB-500, some of these peptides are not approved for therapeutic use. The 
main source for these compounds is represented by the so-called “black markets”. 
4.4 Black market of performance enhancing drugs 
Most of the substances used for doping are usually designed as treatments for specific 
diseases[14,16]. Even blood transfusion and blood doping originate from an emergency 
treatment in the case of critical and copious bleeding. Trafficking of doping products has 
grown exponentially over the decades parallel to evolution of doping itself (appearance of 
new doping agents), pharmaceutical research (new therapeutic targets, new synthesis 
strategies, recombinant technologies) and trading channels (e-commerce)[71]. 
Black market doping substances can be divided in two categories: 
 Approved, controlled substances, used in medical treatments (e.g.: testosterone, 
hGH, tamoxifen…) 
 Unapproved drugs (e.g.: tetrahydrogestrinone, some GHRPs…)  
Collaboration between different authorities such as Police, Customs, Health and Anti-Doping 
Authorities is essential in the fight and prevention of this phenomenon (Figure 1.6). From the 
perspective of the anti-doping laboratories, drugs from the black market, especially non-
approved substances, represent a difficult challenge. The first step consists of 
characterization of the active content. Once a new substance has been identified, reference 
standard material is required to set up a new analytical method or, in the best case, include 
the compound in an already existing screening procedure. Synthesizing reference material 
can be more or less complicated, depending on the nature of the substance. 
Nowadays, peptide hormones represent one of the most popular classes of doping agents 
available on the black markets, as testified by numerous related cases[72–74], publications[75–
77] and the so-called “underground literature” (e.g.: websites, online forums). AAS, selective 
androgen/estrogen modulators (SARMs and SERMs), beta2-agonists (particularly 
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clenbuterol), aromatase inhibitors such as anastrazol, and the AMPK activator 5-amino-4-
imidazolecarboxyamide ribonucleoside (AICAR) appear to easily find their way in illegal 
channels of distributions. 
 
Figure 1.6 Example of black market products seized by Belgian Customs and delivered to 
DoCoLab for identification. 
4.5 Peptide metabolism 
Peptidic drugs follow the same general pharmacokinetics and metabolism principles of 
classic, small molecules, but they are metabolized with different enzymes and through 
different modifications[43].  
In fact, small molecules are mainly metabolized in the liver first by introduction of active and 
polar groups with the help of the cytochrome P450 system (Phase I), then conjugated with 
charged and polar species such as glucuronic acid to further facilitate drug excretion (Phase 
II). In some cases, further modifications (e.g. conjugation of glutathione conjugated with 
acetylcystein) can occur (Phase III)[78]. 
On the other hand, peptidic drugs undergo aspecific enzymatic proteolysis from peptidases 
(also called proteases). As a consequence of this, the native peptide is digested in smaller 
peptide fragments or even single amino acids. All peptidases catalyze the hydrolysis of a 
peptide bond, but they are selective for the position of the substrate and also for the amino 
acid residues close to the bond that undergoes cleavage[79]. 
On the basis of the type of cleavage they catalyze, peptidases can be divided in: 
 exopeptidases, which cleave terminal amino acids from the N-terminus 
(aminopeptidases) or the C-terminus (carboxypeptidases) of a peptide substrate 
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 endopeptidases, such as trypsin and chymotrypsin, which cleave non-terminal amino 
acids from a peptide substrate 
  
Several peptidases can also have deamidating activity at the C-terminus. These metabolic 
reaction consists of the hydrolysis of ther amide bond on the last C-term AA. Figure 1.7 
summarizes these main degradation pathways.  
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Figure 1.7 Scheme of the major peptide degradation pathways. 
 
Peptide metabolism in not usually limited to the liver: an important (in some cases even 
primary) role is played also by plasmatic and kidney peptidases. 
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Peptides with only endogenous AA are generally degraded very fast. Therefore, synthetic 
derivatives were designed with modification such as: 
- substitution of one or more AA 
- use of the D enantiomer AA instead of the L 
- modification at the terminus (C-term amidation, N-term acetylation) 
 
In doping control analysis, the knowledge of the metabolism of a prohibited substance is of 
primary relevance, since targeting (long-term) metabolites can prolong the detection time 
window, thus increasing the possibilities to reveal the abuse of a doping agent. This has been 
described by numerous publications on different classes such as AAS, diuretics, stimulants 
and many others[17,39,80,81]. 
MS-based techniques are currently extensively used in drug discovery and development[82] 
and drug metabolism research, including not only doping control[83] but also clinical and 
forensic pharmacology and toxicology[20,84]. 
First GC-MS and then LC-MS have been established as the premier tool for drug metabolism 
studies (especially LC-MS for being not limited to the analysis to volatile and thermally stable 
compounds)[85]. An additional, major improvement was represented by the development of 
high-resolution mass spectrometry (HRMS) instrumentation, capable to generate molecular 
weight and structural information on the drug metabolites[86]. Particularly when coupled to 
high-performance liquid chromatography (HPLC-HRMS), this technique has evolved into an 
indispensable tool for targeted and untargeted metabolomics analysis. In recent years, 
HPLC-HRMS has become the core technology also for the qualitative and quantitative 
analysis of the proteome (proteomics)[87]. 
Due to the short half-life of most of peptidic-drugs, identification of metabolites can have 
important applications in doping control analysis. At the time this study was started, only 
few studies on the metabolism of prohibited peptides were described in literature: some 
promising results had already been obtained with the identification of insulins[88] and GHRP-
2[89] metabolites that resulted in improved detection of misuse of these peptides. 
Metabolism studies, particularly for non-approved drugs, require in vivo/in vitro models due 
to the limitations in performing administrations in human. Whereas models for small, non-
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peptidic drugs are well established in forensic analysis, with the use of tissue homogenates 
such as human liver microsomes (HLM)[90] or animal models (including chimeric species)[91], 
the development of such models for peptidic substances is a more recent issue, as it will also 
be included in this study. 
4.6 Mass spectrometry of peptides 
The application of MS for the qualitative and quantitative analysis of peptides and proteins 
has had a huge impact in a variety of fields, such as molecular and cell biology, drug 
development, and biomedical and clinical practice. In the last years, the fields of proteomics 
and peptidomics have emerged with the goals to characterize structurally and functionally 
respectively proteins and peptides in complex matrices[87,92]. 
Proteomics is defined as the large-scale study of proteins, particularly their structure and 
functions[87]. On the other hand, the object of peptidomics is the study of the structure and 
biologic properties of peptides present in biologic matrices (fluids, tissues, cells...)[58,93]. 
In both cases, mass spectrometry techniques represent the gold standard, since it allows for 
accurate determination of the molecular mass of known and unknown proteins/peptides as 
well as their sequences (de novo sequencing), especially after the introduction of HRMS 
instrumentation. Protein/peptides identification can be performed with two different 
methods, as shown in Figure 1.8: top-down (analysis of the intact peptide) and bottom-up 
(proteolytic digestion of proteins prior to analysis by mass spectrometry of the peptide 
fragments). 
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Figure 1.8 Bottom-up and top-down approaches used in proteomics for protein 
identification. 
Tandem mass spectrometry (MS/MS) experiments are performed both for top-down and 
bottom-up analyses. In MS/MS experiments, specific precursor ions, corresponding to the 
intact peptide can be selected to be fragmented. The resulting MS/MS spectra present 
fragment ion series (Figure 1.9) which can be used to determine the AA sequence[87,92].  
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Figure 1.9 Nomenclature of sequence-speciﬁc peptide fragments; a-, b-, and c-type ions 
contain the N-terminus; x-, y-, and z- ions contain the C-terminus. At low collision energy 
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values, a, b and y ions are the most commons, as also seen in the identification of peptides 
in Chapters, 6,7and 8. Other characteristic fragments can be formed[92,94]. 
For the identification of an unknown peptide, additional information can be provided by 
deconvolution of the spectrum of the intact peptide. This is most commonly done with 
dedicated softwares, which use algorithms that extrapolate the monoisotopic, single 
charged peak (and thus the molecular mass) from the m/z values of multiple charged peaks 
and their isotopic clusters. 
With the increased popularity of peptide hormones in sport doping, the use of 
proteomics/peptidomics approaches is clearly acquiring relevance also in the doping arena, 
including also this thesis, whose purposes will be described in detail in the next chapter. 
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1 Background and context of the study 
 
Doping control analysis of small peptides can, currently, be considered as a hot topic in sport 
drug testing. The list of prohibited peptide hormones is constantly evolving: for example, at 
the time this study was started (January 2011), desmopressin had just been included in the 
WADA List, whereas some others (e.g.: TB-500) had not been appeared on the scene yet. 
At that time, research on small peptides was mainly focused on LHRH and GHRPs. The first 
LC-MS method for detection of LHRH doping in urine was published in 2008 by Thomas et 
al.[1]. Sample preparation was based on SPE followed by IAP, analogously to previous works 
on bigger peptides (e.g.: insulins)[2]. In 2010, detection of GHRP-2 and its long-term 
metabolite (AA 1-3) in urine was achieved by Okano et al. using solid-phase extraction for 
sample pretreatment. In 2011, the first multi- analyte, single-class method for GHRPs was 
published[3], followed in 2012 by the first multi- analyte, multi-class method[4]. 
Therefore, from the analytical point of view, the following trends could be observed: 
 From SPE+IAP to SPE only for sample preparation 
 From single-analyte methods to multi-class methods 
 Research on the identification of metabolites and then inclusion in methods to 
increase detection windows  
Simultaneously, several publications started to highlight the phenomenon of black market of 
peptides hormones with performance enhancing properties, particularly GHRPs and GHRH 
analogues[5–7]. 
In such context, this research has been carried at the Ghent University Doping Control 
Laboratory (DoCoLab), with the overall aim of implementing suitable analytical methods for 
detection of small peptide hormones. The study has been performed along three main lines 
of research: 
 Development of methods for the qualitative analysis of prohibited peptides in urine 
and/or plasma 
 Development of in vitro models to study the metabolism of prohibited peptides 
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 Identification of unknown peptide hormones with doping potential from black 
markets 
 
2 Detection of desmopressin in plasma and urine 
 
The first part of the study will focus on the development of new LC-MS/MS methods for 
detection of desmopressin in human plasma and urine. The AVP analogue desmopressin was 
added to the WADA List in 2011 as an example of a masking agent[8]. In fact, this peptide can 
act as a plasma volume expander by decreasing significantly hematocrit and hemoglobin 
values, and thus masking blood doping. 
No LC-MS-based methods for desmopressin plasma had been described before the 
beginning of the study, but only immunoassays were reported in the literature[9,10]. To fit 
anti-doping purposes, the method should be able to detect desmopressin unambiguously at 
the femtomole range and allow for a relatively high throughput (20-25 samples per day). 
To achieve this goal, SPE-based sample preparation procedures were evaluated, comparing 
different SPE stationary phases and different protocols. Detection methods were developed 
using a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) 
system. The MS detector consisted of a low-resolution triple-stage quadrupole mass 
spectrometer, as this was the only type of MS system available in the laboratory at the time 
of the desmopressin studies described in Part II of this thesis.  
In order to evaluate which matrix is preferred for monitoring desmopressin, detection 
methods for confirmation and screening in both plasma and urine will be compared. 
 
3 Peptide hormones and black markets 
 
In Part III of this thesis, illegal trading of peptide hormones will be discussed, particularly 
from the perspective of the anti-doping laboratories. 
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Over the last years, numerous new products have found their way into black markets[5–7,11]. 
Identification of these emerging doping substances is the first important step toward 
detection of their misuse. The existence of a new black market product is usually revealed in 
two ways: 
 Anecdotal evidence: online black markets, internet discussion forums (e.g.: 
bodybuilding forums) 
 Authorities’ actions: confiscation of illegal products by Police or Customs. 
These two sources are both used by the laboratory to discover new prohibited peptide 
hormones. Particularly, DoCoLab started collaboration with the Belgian Laboratory of 
Customs and Excise in Leuven to identify peptide hormones in black market formulations. 
Several confiscated products by the Customs were sent to the laboratory for identification. 
Additionally, several products have been purchased directly from online distributors. 
For identification purposes, methodologies based upon HRMS coupled to ultra-high-
performance liquid chromatography (UHPLC-HRMS), using either bottom-up and top-down 
approaches will be developed. 
The results and characterization of new potential doping agents will be described in Part III. 
 
4 In vitro metabolism of small peptides 
 
As first shown by the work of Okano et al.[12], monitoring metabolites of small peptides can 
increase the chances to detect a positive sample. Since performing administration studies of 
prohibited peptide hormones is not always allowed because of ethical constraints, it is 
necessary to develop alternative models to elucidate their metabolism, analogously to other 
classes of doping agents such as designer steroids and synthetic cannabinoids[13,14]. 
In part IV of this thesis, the use of in vitro models to study small peptide metabolism for 
doping control purposes will be evaluated and compared with recently published literature. 
For the evaluation, the results of the following model peptides will be discussed: 
desmopressin, LHRH, leuprolide, TB-500, GHRP-2, GHRP-6, and hexarelin. Results will be 
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compared with those obtained with established models (incubation with fresh serum and 
plasma)[15]. For in vitro experiments, the use of human microsomes and fraction S9 from 
human liver and kidney were tested, despite the fact that these models are conventionally 
used only for small, non-peptidic drugs. Additionally, deamidation was evaluated by 
incubation of the peptides with the deamidating enzyme α-chymotrypsin. After incubation, 
the metabolites were identified by UHPLC-HRMS in MS/MS mode. The results of these 
experiments will be discussed. 
 
5 Screening method 
 
Over the last years, the number of small peptidic doping agents has increased. With 
significant efforts from WADA and its laboratories, the knowledge on their detection and on 
their metabolism has significantly incremented. Main strategies for detection were 
established; moreover, reference standard and certified reference materials to perform 
research and to develop analytical methods became more available. 
Depending on the fact that a new peptidic dopingagent is approved for therapeutic use or 
not, there are two major paths that lead from its discovery to its detection (Figure 2.1).. As it 
will also be discussed in this thesis, an unapproved drug (e.g.: TB-500) yields additional 
problems to the doping control analyst.  
 49 
 
 
Figure 2.1 Scheme of the paths from discovery to doping control analysis of small peptide 
hormones. 
 
However, regardless of the status of the peptide, the final goal of this investigation is the 
implementation of the analysis of small peptide hormones in the laboratory. 
As these compounds shared similar analytical issues, a multi-analyte method is preferred in 
order to increase efficiency of testing and reduce costs. 
A UHPLC-HRMS method will be developed and validated in order to detect 31 small 
peptides, including metabolites: 
- Arginine vasopressin analogues: desmopressin, lysine vasopressin, terlipressin 
- TB-500 and 3 TB-500 metabolites  
- GHRPs: GHRP-1,-2,-4,-5,-6, ipamorelin, alexamorelin, hexarelin, and 5 metabolites (1 
for GHRP-2, 2 for GHRP-6, 2 for hexarelin) 
- Human LHRH and analogues: buserelin, deslorelin, goserelein, leuprolide, nafarelin, 
triptorelin, and 3 metabolites (2 for leuprolide, 1 for naftarelin) 
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- AOD9604 
Sample preparation will be based on SPE, similarly to previous works[4,16]. UHPLC-HRMS will 
be used for the development of the method. All compounds must be detected at sub ng/mL 
concentration. 
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1 Abstract 
 
This Chapter describes the development of a liquid chromatography-electrospray tandem 
mass spectrometry (LC-ESI-MS/MS) method for detection of desmopressin in human plasma. 
Desmopressin is a synthetic analogue of the antidiuretic hormone arginine vasopressin and it 
might be used by athletes as masking agent in the frame of blood passport controls. 
Therefore, it was recently added by the World Anti-Doping Agency (WADA) to the list of 
prohibited substances in sport as a masking agent. 
Mass spectrometry characterization of desmopressin was performed with a high-resolution 
Orbitrap-based mass spectrometer. Detection of the peptide in the biological matrix was 
achieved using a triple quadrupole instrument with an electrospray ionization (ESI) interface 
after protein precipitation, weak cation solid phase extraction and HPLC separation with an 
octadecyl reverse phase column. Identification of desmopressin was performed using three 
product ions, m/z 328.0, m/z 120.0, and m/z 214.0, from the parent ion at m/z 535.5. 
The extraction efficiency of the method at the limit of detection was estimated at 40% 
(n=10), the ion suppression at 5% (n=10), and the limit of detection was 50 pg/mL (S/N> 3). 
Selectivity of the method was verified against several endogenous and synthetic 
desmopressin related peptides. The performance and the applicability of the method were 
tested by analysis of clinical samples after administration of desmopressin via intravenous, 
oral, and intranasal routes. Only after intravenous administration, desmopressin could be 
successfully detected. 
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2 Introduction 
 
Desmopressin, 1-desamino-8-D-arginine-vasopressin (dDAVP), is a synthetic analogue of 
arginine [Arg8]-vasopressin (AVP), a cyclic peptide hormone with antidiuretic properties, 
synthesized in the hypothalamic cells and released from neurohypophysis. Desmopressin 
(monoisotopic mass: 1068.4269 Da) is obtained by deamination at the N-terminal 1 position 
of AVP and replacement of 8-L-arginine with its D-isomer (Figure 3.1)[1–3]. 
 
Figure 3.1 Compared to arginine vasopressin, Cys1 in desmopressin has been deaminated, 
and the Arg8 is in the dextro rather than the levo form. 
Compared with AVP, desmopressin has a longer lasting and more potent antidiuretic effect 
and is devoid of vasopressor effects[2,4,5]. Desmopressin is therapeutically used for the 
treatment of diabetes insipidus[4,5], primary nocturnal enuresis (bed wetting) [6–10] type I von 
Willebrand disease, and hemophilia A[11–14]. 
Desmopressin can induce hemodilution decreasing hematocrit levels and hemoglobin 
concentrations. These values are important hematological parameters used to detect blood 
doping in sports[15,16]. 
Therefore, desmopressin has recently been added by the World Anti-Doping Agency (WADA) 
to the 2011 Prohibited List as a masking agent[17]. 
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Previous methods for the detection of desmopressin in biological fluids were performed only 
for clinical purposes, by immunoassays. These methods provided sensitive and cost effective 
analyses[8,18–22], but with some important limitations, in particular concerning specificity[23]. 
Liquid chromatography-mass spectrometry (LC-MS) shows good sensitivity together with a 
high degree of selectivity and specificity to allow for unequivocal confirmation of the 
presence of a substance based on its molecular weight. Hence LC-MS methods have become 
the method of choice for the analysis of peptide hormones[24]. 
Until now, only one study using LC-MS to identify desmopressin has been published[25]. This 
method was applied for the analysis of skin samples and has a limit of detection (LOD) of 10 
ng/mL (≈ 10 picomole). Obviously, this matrix is not applicable in the field of sport drug 
testing. Hence, the present work had the aim to develop and validate a LC-ESI-MS/MS 
method for detection of desmopressin in plasma fit for anti-doping purposes.  
 
3 Materials and methods 
 
3.1 Chemicals and reagents 
All the chemicals and solvents used for sample pretreatment and chromatography were 
analytical grade or HPLC grade. Desmopressin was a kind gift from Ferring Pharmaceuticals 
(Malmö, Sweden). AVP and [deamino-Cys1, Val4, D-Arg8]-vasopressin were purchased from 
Sigma Aldrich (Saint Louis, USA). Oxytocin, [Lys8]-vasopressin, and terlipressin were 
purchased from Selleck Chemicals LLC (Houston, USA). Desmopressin and analogues were all 
available as acetate salts. Stock and working solution were all prepared using 2% acetic acid 
(HOAc) aqueous solutions. Acetonitrile (ACN) and water (H2O) were purchased from BioSolve 
(Lexington, USA); methanol (MeOH) was purchased from Fisher Scientific (Aalst, Belgium); 
25% ammonia (NH4OH) aqueous solution and glacial HOAc were purchased from Merck 
(Darmstadt, Germany); trifluoroacetic acid (TFA) was purchased from Sigma-Aldrich. 
Saturated ammonium sulfate ((NH4)2SO4) solution was prepared by dissolving 800 g of 
(NH4)2SO4 (Merck, Darmstadt, Germany) in 1000 mL of H2O at room temperature. The 
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resulting solution was gently poured into a second glass bottle in order to get rid of the 
undissolved crystals of (NH4)2SO4, then 20 mL of 25% NH4OH were added to 1 l of the 
(NH4)2SO4 solution. 
Only low binding microcentrifugal vials, type Eppendorf (Eppendorf, Hamburg, Germany) 
and low retention pipette tips (Sorenson Biosciences, Salt Lake City, USA) were used to 
prepare stock solutions (100 µg/mL) and working solutions (10 ng/mL). AVP was always 
added to desmopressin working solutions at a concentration of 2.5 ng/mL, in order to 
prevent desmopressin adsorption to solid surfaces. 
3.2 Plasma samples 
Method development and validation were performed using left-over plasma samples 
obtained from Red Cross Blood Transfusion Center (Gent, Belgium, approval number 
20100609). Desmopressin containing plasma samples were obtained from the Department 
of Internal Medicine (Endocrinology and Hematology) of the Ghent University hospital, with 
the approval of the Ethical Committee of the Ghent University (reference: B67020108809). 
3.3 Sample preparation 
2 mL of plasma were spiked with 50 µl of [deamino-Cys1, Val4, D-Arg8]-vasopressin (50 
ng/mL) as internal standard. Then, 2 mL of saturated (NH4)2SO4 solution, containing 2% 
NH4OH, were added and the samples were centrifuged (4100 g, 1 h, 2°C) to precipitate 
plasma proteins. A further purification of the supernatant was performed by solid phase 
extraction with Oasis® WCX (60 mg) cartridges, purchased from Waters (Milford, USA). The 
column was first activated with 2 mL of MeOH and subsequently rinsed with 2 mL of H2O. 
After the sample was loaded, the column was washed first with 2 mL of 5% NH4OH aqueous 
solution, then with 2 mL of 60:40 H2O:MeOH mixture. Finally, samples were eluted with 1.25 
mL of a solution consisting of 80:20 MeOH:(5% HOAc in H2O). The eluate was subsequently 
evaporated to dryness with a centrifugal evaporator (45°C, 240 g, 6-8 h), and then dissolved 
in 40 µl of 95:5 H2O:ACN, 0.1% HOAc, 0.01% TFA prior to LC-MS analysis. 
3.4 Liquid chromatography  
HPLC separation was achieved with a Surveyor MS Pump Plus coupled with a Surveyor Plus 
autosampler (Thermo Scientific, Bremen, Germany) using a Zorbax 300SB-C18 reverse-phase 
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column (1.0 x 50 mm, 3.5 µm) protected with a Zorbax 300SB-C8 guard column, both from 
Agilent Technologies (Santa Clara, USA). The use of the C8 guard column was adopted from a 
previous work from Thevis et al.[26]. 
For each sample, 30 µl were injected. A binary gradient was used: mobile phase A consisted 
of H2O, 0.1% HOAc, 0.01% TFA; mobile phase B consisted of ACN, 0.1% HOAc, 0.01% TFA. 
Gradient elution was as follows: 95% A for 1.5 minutes, then decreased linearly to 0% A in 
8.5 minutes, and held at 0% A for 5 minutes, followed by an increase to 95% A in 0.1 
minutes. Then the system was equilibrated for 10 minutes before next injection (total run 
time: 25 minutes). A constant flow rate of 50 µl/min was maintained. 
3.5 Mass spectrometry 
MS/MS method development for detection of desmopressin in human plasma was 
performed on a TSQ Quantum Discovery Triple Stage Quadrupole Mass Spectrometer 
(Thermo Scientific, Bremen, Germany) equipped with an ESI source operating in positive 
mode. The ESI–MS operating variables used in this study were as follows: capillary voltage, 
3.5 kV; source temperature, 350 °C; sheat gas pressure, 30 psi; auxiliary gas pressure, 10 psi; 
tube lens offset, 84V. 
Mass spectrometry characterization of desmopressin and related peptides was performed 
on an Exactive benchtop Orbitrap-based mass spectrometer (Thermo Scientific, Bremen, 
Germany) operating in positive HCD scan at 50 eV. The sheath gas was set to 60 (arbitrary 
units), the aux gas set to 30 (arbitrary units) and the capillary temperature set to 350°C. The 
capillary voltage and spray voltage were set to 30 V and 3 kV, respectively. The instrument 
was operated in full scan mode from m/z 60–1200 at 100,000 resolving power. The data 
acquisition rate was 1 Hz. 
3.6 Disulfide bridge reduction 
In order to get additional information on the MS behavior of desmopressin, reduction of the 
disulfide bridge (Mpa1-Cys6) was performed by adding 200 µl of dithiothreitol in 0.2 mM 
ammonium acetate buffer at pH=5.5 (both from Sigma-Aldrich) to readily prepared solutions 
of the peptide and incubating the resulting solution for 30 minutes at 56 °C. 
3.7 Validation 
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In accordance with Eurachem validation guidelines[27], 10 human plasma samples, were 
spiked at different levels (5, 10, 25, 50, 100 pg/mL) to determine the LOD. 
The detection limit was defined as the lowest level at which a compound could be identified 
in all 10 plasma samples with  the diagnostic ions present with a signal-to-noise (S/N) ratio 
greater than 3 and a retention time difference of less than 0.1 min to the reference. 
Selectivity was tested by analysing plasma samples spiked with desmopressin and its 
analogues at a concentration of 100 pg/mL.  
The analogues included the endogenous hormones AVP and oxytocin, and the synthetic 
derivatives [deamino-Cys1, Val4, D-Arg8]-vasopressin, [Lys8]-vasopressin, and terlipressin. 
Specificity was tested during the validation procedure in order to check the absence of 
endogenous interferences. The 10 blank plasma samples used for determining analytical 
performances of the method were extracted and analyzed as described above. 
3.8 Extraction efficiency and matrix effect  
To evaluate the extraction efficiency, the 10 negative plasma samples, used for the 
validation, were spiked with desmopressin at 50 pg/mL and processed together with non-
spiked plasma samples. The extracts of the non-spiked plasma samples were spiked after 
evaporation and before HPLC injection. After analysis the obtained peak areas for the 
product ion at m/z 328.0 of the two sets of samples were compared.  
Matrix effect was evaluated by comparing the peak areas (m/z 328.0) of the plasma samples 
spiked after extraction with a reference solution of desmopressin at 50 pg/mL, 
corresponding to a 100% recovery (0% matrix effect). 
3.9 Excretion studies 
7 plasma samples from patients who received desmopressin were used in the study. Four 
patients received desmopressin via intranasal (≈ 10 µg/dose), two orally (200 µg) and one 
intravenously (20 µg). Blood samples were immediately centrifuged and plasma was 
separated. When not directly analyzed, plasma samples were stored at <-20°C awaiting 
analysis. 
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4 Results and discussion 
 
4.1 Mass spectrometry 
Direct infusion of desmopressin and analogues was performed in order to determine the 
best mass spectrometry conditions for the design of the MRM method. A full scan MS 
analysis was first performed in order to identify the most abundant precursor ions and 
subsequently the collision energy was optimized for the most diagnostic fragments.  
Desmopressin showed excellent ionization, due to the presence of an arginine residue (Arg8), 
containing the guanidinium group with a high proton affinity. The double charged ion 
[M+2H]+2 was observed as base peak for desmopressin (Figure 3.2) but also for the 
analogues. The single charged ion [M+H]+ only achieved a relative abundance of 20%. The 
collision-induced dissociation of desmopressin base peak (m/z 535.5) led to the formation of 
several fragments. Fragment ions at m/z 328.0, m/z 120.0 and m/z 214.0 were selected as 
diagnostic. Several other product ions, also present in the spectrum, were also recorded 
during mass spectrometry characterisation, but they were not specific or not sensitive 
enough using a criteria of S/N >3 to be considered for reliable detection. The other 
vasopressin-related peptides presented similar ESI spectra. Also, the ion [M+2H]+2 appeared 
as base peak in the full scan MS spectra of each peptide. Additionally, the peptides 
presented several common fragments, but different precursor ions and retention times were 
observed, therefore method selectivity was guaranteed. Results from infusion experiments 
for MS/MS optimization of the investigated compounds are summarized in Table 3.1.  
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Figure 3.2 High-resolution full scan MS spectra of desmopressin (a), and isotopic pattern of 
its base peak [M + 2H]2+ (b).  
Table 3.1 Amino acid sequence, retention times and MRM conditions for ESI-MS/MS 
analysis of desmopressin and related peptides. Desmopressin and its analogues present 
several common product ions, but different retention time and parent ion. The double 
charged ion resulted to be the most abundant for all the investigated peptides. 
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The three diagnostic ions selected for MRM method were further investigated by high-
resolution mass spectrometry. Figure 3.3 shows the fragmentation patterns of the native (a) 
and the reduced (b) peptide generated by HCD at 50 eV at high resolution. All the relevant 
fragments are single-charged and some of them present a neutral loss of NH3. Moreover, it is 
possible to notice that in the native molecule all the significant high-mass fragments (y2-NH3, 
y3-NH3, y3, b6) contain the Arg8. The b6-NH3 fragment, which presents an intramolecular 
disulfide bridge between C1 and C6 and is adjacent to a proline residue, represents the only 
exception[28]. Reduction of the disulfide bridge provided additional information on the MS 
characterization of desmopressin, yielding to the identification of the complete y3-y7 
sequence. 
The contemporary presence in fragment ion y3 of Arg8 and Pro6 at the N-terminal, which 
usually causes enhanced fragmentation attributed to the greater basicity of proline 
substituted nitrogen group[29], can explain the elevated abundance of this fragment in the 
MRM mode. 
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Figure 3.3 HCD spectra of desmopressin acquired at 50eV (a). The fragmentation scheme 
shows that all the most abundant high MW fragments contain the arginine residue, except 
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b6, that is stabilized by the disulfide bridge. Reduction of the disulfide bridge (b) yield to 
the identification of the sequence y3-y7. 
4.2 Liquid chromatography 
Chromatographic separation was achieved with a C18 column, which allowed satisfactory 
peak shapes and chromatographic retention for desmopressin, the internal standard and the 
carrier peptide. A high percentage (90%) of ACN was required to elute desmopressin, which 
presented an average retention time (tR) of 10.07, as well as for the IS (tR=10.75 min). The 
carrier peptide AVP that contains the terminal amino moiety eluted earlier (tR=3.63 min). 
Additionally, other desmopressin related peptide, including the endogenous hormone 
oxytocin and the synthetic analogues [Lys8]-vasopressin, and terlipressin were analyzed to 
further investigate method selectivity. Results, also summarized in Table 3.1, demonstrated 
that the chromatography is sufficient to separate desmopressin from these peptides. In fact, 
oxytocin elute at 9.88 min, [Lys8]-vasopressin at 3.50 min, and terlipressin at 3.76 min. 
4.3 Sample preparation 
Since no LC-MS based method for detection of desmopressin in plasma has been described 
previously, the sample preparation procedures available from the literature were all related 
to the function of immunoassays. These approaches are based mainly on previous work of 
Lundin et al.[21,22]. Desmopressin is a small, highly basic peptide, resulting in good solubility, 
without a significant tertiary structure that can undergo denaturation during protein 
precipitation. Therefore Lundin et al.[21] successfully used protein precipitation with ice-cold 
acetone as sample clean-up. To optimize this protein precipitation step, the application of 
acetone, methanol, saturated (NH4)2SO4 and ethanol
[30] were evaluated during method 
development. Deproteination of the samples using saturated (NH4)2SO4, gave the best 
results regarding S/N response. Additionally, omitting the use of an organic solvent to 
precipitate bulk proteins avoids the requirement to evaporate the deproteinated sample 
before application to the SPE in the next step. Finally, the use of protein precipitation 
allowed a 5-fold increase of the MS response compared with samples that were processed 
only with SPE. To further decrease sample preparation time, 15 and 30 min centrifugation 
instead of 60 min was considered. However, due to the lower centrifugation time, 
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deproteination was less complete. Using centrifugation devices with higher speed can 
further shorten centrifugation times. 
SPE was considered to further concentrate and desalt the samples. In particular, cation 
exchange columns were investigated, because desmopressin is a basic peptide with a pKa 
value of approximately 12. Mixed-mode ion-exchange (MCX) columns were initially 
investigated. However, desmopressin could not be recovered from this type of column 
during the elution step since this type of column is only applicable for weak basic 
compounds. 
Weak-cation ion exchange  (WCX) columns proved to be particularly suitable for the clean-
up of strong basic compounds  allowing, compared to octadecyl (C18) and hydrophilic-
lipophilic balance (HLB) sorbents, to eliminate efficiently acid and slightly basic matrix 
components. These resulted in a higher grade of purification.  
Since the WCX protocol requires a basic pH to load the samples on the SPE column, the 
(NH4)2SO4 saturated solution was basified with NH4OH (pH 9.2). No differences in 
desmopressin responses were registered for protein-precipitation compared with the non-
basified (NH4)2SO4 saturated solution. The presence of 20% water in the elution solvent, 
resulting in a longer evaporation time, guaranteed the best results in terms of sensitivity.  
4.4 Choice of internal standard and carrier peptide 
[deamino-Cys1, Val4, D-Arg8]-vasopressin was chosen as internal standard since it presents a 
very similar chemical structure, pKa, and retention times (ΔtR≈ 0.7 min) to desmopressin, 
and therefore a similar behavior during the entire analytical process. Since the degree of 
adsorption of a peptide or protein is not always predictable, several precautions were 
adopted to prevent this phenomenon, including the use of low binding plastic and the use of 
a carrier peptide. AVP was considered as a suitable carrier peptide for working solutions 
since it presents a very different retention time (ΔtR≈ 6.4 min) from the target analyte, 
which means no interferences with its detection, and, additionally, a low cost for the 
standard reference. We registered only a slight decrease (approximately 10´%) in MS 
response when diluted working solutions of 10 ng/mL of desmopressin, not containing AVP 
as carrier peptide, were analyzed, whereas no significant differences were recorded when 
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AVP was added to plasma sample (500 ng/mL) at the beginning of the sample preparation. 
Hence, desmopressin adsorption did not occur or was negligible during sample preparation. 
Additionally, stability of desmopressin working solution stored at 4°C was tested by 
preparing a new solution (10 pg/mL) every month and comparing it with the previous by LC-
MS analysis. After 4 months, no significant difference was noticed in peak areas of the 
various solutions. Moreover, desmopressin working solution was demonstrated to be stable 
after incubation at 56°C for 6 hours. 
4.5 Method validation 
The method showed an LOD of 50 pg/mL, with a signal to noise ratio (S/N) greater than 3 for 
the three transitions in all plasma samples that were analyzed. Maximum tolerance windows 
(% of base peak m/z 328.0) were set at ±10% (absolute) for m/z 120.0 and ±5% (absolute) for 
m/z 214.0, according to the WADA identification criteria for LC-MS qualitative assays[31] that 
recommend the use of minimum two transitions for MRM-based methods. Nevertheless, 
using only one transition is also allowed. According to the abundance recorded using the 
product ion at m/z 328.0, the average extraction efficiency (n=10) of the preparation was 
estimated at 40% (±4%). Signal reduction due to ion suppression in the ESI source (n=10) was 
limited to 5% (±14%). 
The method also exhibited good selectivity since the related peptides presented different 
retention times, as shown in Table 3.1. Mass overlapping for mass spectrometry detection 
was avoided, thereby ensuring analytical selectivity. AVP, [Lys8]-vasopressin, and terlipressin, 
whose N-terminal is not deaminated, elute earlier (3.5-3.80), whereas desmopressin, 
[deamino-Cys1, Val4, D-Arg8]-vasopressin (both deaminated) and oxytocin (which presents 
the hydrophobic amino acid isoleucine) require a higher percentage of organic solvent. 
The method can be used for the analysis of an elevated number of samples per batch and 
the whole analysis can be performed in a single day, since the only time consuming step 
(evaporation of the SPE eluate) requires only few hours. 
4.6 Method application 
The suitability of our method was evaluated by the analysis of 7 plasma samples from 
patients who received desmopressin. Four patients received desmopressin intranasally, two 
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orally and one intravenously. Administered dose and collection times are summarized in 
Table 3.2. Detection of desmopressin after oral administration could not be achieved, even 
taking into account only the most abundant transition (m/z 535 -> 328, LOD= 10 pg/mL). 
Indeed, orally administered desmopressin has a very low bioavailability. Osterberg et al.[19] 
reported maximum plasma levels < 50 pg/mL (t= 90 min) after oral administration of a 
therapeutic dose of 240 µg. Similarly, desmopressin was not detectable after nasal 
administration. The lower dose (≈ 10 µg) and the generally lower bioavailability of this type 
of formulation could explain the non-detection. After intravenous administration of a 20 µg 
dose, desmopressin could be detected in an unambiguous way (Figure 3.4b). 
 
 
Figure 3.4 Extracted ion chromatograms for the product ions m/z 328.0, m/z 120.0, m/z 
214.0 (precursor ion m/z 535.5) respectively in a blank plasma (a), after fortification with 
 72 
 
desmopressin at LOD concentration (50 pg/mL) (b), before (c) and after administration of 
intravenous desmopressin (d). Samples were all prepared and analyzed according to the 
described assay. 
 
Table 3.2 Summary of blood specimens from excretion study, collected after 
administration of desmopressin via different routes. 
 
 
It can be concluded that desmopressin detection in plasma related to anti-doping analysis is 
not realistic after oral or intranasal administration. In particular, since oral administration 
has shown to affect hematocrit levels[12] and intravenous application seems unlikely due to 
its invasive nature, it will be necessary to consider other detection strategies to increase the 
possibility to detect the misuse of this peptide by LC-MS.  According to Agerso et al.[20], an 
important fraction of desmopressin is eliminated from the body via renal clearance. Hence 
urinary detection of desmopressin will be further investigated. 
 
5 Conclusions 
 
For the first time a sensitive LC-ESI-MS/MS method for the detection of desmopressin in 
human plasma for doping purposes was described. Validation of the method showed an LOD 
of 50 pg/mL when three transitions were considered, and 10 pg/mL when only the most 
abundant transition (m/z 328) was monitored. The method exhibited also good selectivity 
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and specificity. Application of the method to administration samples showed that 
desmopressin was detectable when administered intravenously, but not after oral and 
intranasal administration. The results of the analysis of the administration samples are in 
agreement with the literature describing low bioavailability and short plasmatic half-lives 
after oral and intranasal application, hampering its detection. 
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Chapter 4 
Detection of desmopressin in urine by liquid-
chromatography-tandem mass spectrometry 
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desmopressin in human urine by LC-ESI-MS/MS after urine delipidation. Biomed. Chromat. 
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1 Abstract 
 
The World Anti-Doping Agency (WADA) has recently added desmopressin, a synthetic 
analogue of the endogenous peptide hormone arginine vasopressin, to the Prohibited List, 
due to the potential masking effects of this drug on hematic parameters useful to detect 
blood doping. 
A qualitative method for detection of desmopressin in human urine by high performance 
liquid chromatography-electrospray tandem mass spectrometry (LC-ESI-MS/MS) has been 
developed and validated. Desmopressin purification from urine was achieved by means of 
delipidation with a 60:40 di-isopropyl ether/n-butanol and solid phase extraction with WCX 
cartridges.  
The lower limit of detection was 25 pg/mL. Extraction recovery was determined as 59.3% 
(SD= 29.4), and signal reduction due to ion suppression was estimated  to be 42.7% (SD= 
12.9). The applicability of the method was proven by the analysis of real urine samples 
obtained after desmopressin administration via intravenous, oral and intranasal, achieving 
unambiguous detection of the peptide in all the cases. 
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2 Introduction 
 
Desmopressin (1-desamino-8-D-arginine-vasopressin, dDAVP) is a synthetic derivative of the 
naturally occurring peptide hormone arginine vasopressin (AVP)[1,2], developed with the aim 
of having a longer lasting and more potent antidiuretic effect than AVP[2]. Recently, it has 
been demonstrated that the oral administration of desmopressin after EPO intake provokes 
rapid hemodilution, which causes the hematocrit to decrease[3,4]. In doping control analysis, 
hematocrit is an indirect marker of erythropoietins (EPOs) misuse and blood doping[5]. 
For this reason, the World Anti-Doping Agency (WADA) has added desmopressin to the 
Prohibited List as a masking agent and, consequently, methods for detection of 
desmopressin need to be developed to control its misuse[6]. Several detection methods using 
immunoassays for plasma and urine have been described[7–11]. These methods are very 
sensitive, having limits of detection (LODs) in the low pg/mL range, but they do not always 
provide the high grade of specificity and selectivity necessary in doping control analysis. 
Our group developed a LC-MS/MS method for detection of desmopressin in plasma[12]. 
Although the method was sensitive (lower limit of detection: 50 pg/mL), it allowed only the 
detection of desmopressin after intravenous injection, but not for the oral and intranasal 
formulations, probably due to the low bioavailability of the drug when administered by 
these two routes[8]. According to Agerso et al.[9], an important part of the administered dose 
is eliminated by renal excretion. Recently, the detection of desmopressin in urine after 
intranasal and oral administration by using a hybrid quadrupole/time-of-flight (Q-TOF) mass 
spectrometer was described[13] showing good sensitivity. In the present study, a liquid 
chromatography-triple quadrupole tandem mass spectrometry method to detect 
desmopressin in urine is presented and was applied to the detection of desmopressin after 
intravenous, oral and intranasal administration. To improve the detection limit of the 
method, delipidation of the urine samples was also investigated. 
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3 Materials and methods 
 
3.1 Chemicals and reagents 
All the chemicals and solvents used for sample pretreatment and chromatography were 
analytical grade or HPLC grade. Desmopressin was a kind gift from Ferring Pharmaceuticals 
(Malmö, Sweden). AVP and [deamino-Cys1, Val4, D-Arg8]-vasopressin were purchased from 
Sigma Aldrich (Saint Louis, USA). All the peptides were available as acetate salts. Stock and 
working solutions were all prepared using aqueous solutions containing 2% acetic acid 
(HOAc). Acetonitrile (ACN) and water (H2O) were purchased from BioSolve (Lexington, USA); 
methanol (MeOH) was purchased from Fisher Scientific (Aalst, Belgium); 25% ammonia 
(NH4OH) aqueous solution, ammonium chloride (NH4Cl) and glacial HOAc were purchased 
from Merck (Darmstadt, Germany); trifluoroacetic acid (TFA), di-isopropyl ether and n-
butanol were purchased from Sigma-Aldrich. 
Ammonia buffer solution was prepared by dissolving 40 g of NH4Cl in 100 mL of H2O at room 
temperature. The resulting oversaturated solution was gently poured into a second glass 
bottle in order to get rid of the undissolved crystals of NH4Cl, and then NH4OH were added 
to the NH4Cl solution until the final pH of 9.5 was reached. 
Only low binding 1.5 mL vials (Eppendorf, Hamburg, Germany) and low retention pipette tips 
(Sorenson Biosciences, Salt Lake City, USA) were utilized to store stock solutions (100 µg/mL) 
and to prepare working solutions (10 ng/mL). AVP was always added to desmopressin 
working solutions at a concentration of 500 ng/mL to prevent desmopressin adsorption to 
solid surfaces. 
3.2 Sample preparation 
3 mL of urine were spiked with 2 ng of [deamino-Cys1, Val4, D-Arg8]-vasopressin as internal 
standard. The samples were then acidified (pH= 3.5-4.0) by adding 500 µl of 5% HOAc 
aqueous solution. Samples were then delipidated by adding 5 mL of di-isopropyl ether:n-
butanol 60:40 solution, vortexing (30 seconds) and then centrifuged (4100 g, 20 minutes, 
5°C). The upper layer was discarded and a second delipidation step with di-isopropyl ether:n-
butanol 60:40 was performed at the same conditions but with a basic pH (9.5-10.0) after 
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addition of 500 µl of ammonia buffer. After centrifugation, the upper layer was discarded 
again and the remaining organic solvent was rapidly eliminated by evaporation under a 
gentle nitrogen stream (5 minutes, 30°C). The delipidated urines were then further purified 
by solid phase extraction (SPE) with Oasis® WCX (60 mg) cartridges, purchased from Waters 
(Milford, USA) with a procedure derived from our previous work on plasma. The eluate was 
subsequently evaporated to dryness with a centrifugal evaporator (45°C, 240 g, 6-8 h), and 
then dissolved in 40 µl of 95:5:0.1:0.01 H2O:ACN:HOAc:TFA prior to LC-MS analysis.  
3.3 LC-MS 
The samples were analyzed using the same LC-MS conditions as described in the previous 
work in plasma (Chapter 3). HPLC separation was achieved with a Surveyor MS Pump Plus 
coupled with a Surveyor Plus autosampler (Thermo Scientific, Bremen, Germany) using a 
Zorbax 300SB-C18 reverse-phase column (1.0 x 50 mm, 3.5 µm) protected with a Zorbax 
300SB-C8 guard column, both from Agilent Technologies (Santa Clara, USA). 
A binary gradient was used: mobile phase A consisted of H2O, 0.1% HOAc, 0.01% TFA; mobile 
phase B consisted of ACN, 0.1% HOAc, 0.01% TFA. Gradient elution was as follows: 95% A for 
1.5 minutes, then decreased linearly to 0% A in 8.5 minutes, and held at 0% A for 5 minutes, 
followed by an increase to 95% A in 0.1 minutes. Then the system was equilibrated for 10 
minutes before next injection (total run time: 25 minutes). A constant flow rate of 50 µl/min 
was maintained. For each sample, 30 µl were injected. 
MS/MS detection was performed on a TSQ Quantum Discovery Triple Stage Quadrupole 
Mass Spectrometer (Thermo Scientific, Bremen, Germany) equipped with an ESI source 
operating in positive mode. The ESI–MS operating variables used in this study were as 
follows: capillary voltage, 3.5 kV; source temperature, 350 °C; sheat gas pressure, 30 psi; 
auxiliary gas pressure, 10 psi; tube lens offset, 84V. 
3.4 Validation 
In accordance with Eurachem validation guidelines[14], 10 different blank human urine 
samples, were spiked at different desmopressin levels (10, 25, 50, 100, 200 pg/mL) to 
determine the LOD. The detection limit was defined as the lowest level at which a compound 
could be identified in all 10 urine samples with both the diagnostic ions present with a 
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signal-to-noise (S/N) ratio greater than 3 and a retention time difference of less than 0.1 min 
with the reference, as recommended by WADA criteria for qualitative assays[15].  
Specificity was tested during the validation procedure. The 10 blank urine samples used for 
determining detection capability were extracted and analyzed as described above. 
3.4 Extraction recovery and matrix effect 
To evaluate the extraction recovery, the 10 negative urine samples, used for the validation, 
were spiked with desmopressin at 50 pg/mL and processed together with non-spiked urine 
samples. The extracts of the non-spiked urine samples were spiked after evaporation and 
before HPLC injection. After analysis the obtained peak areas of the two sets of samples 
were compared.  
Matrix effect was evaluated by comparing the peak areas of the urine samples spiked after 
extraction with a reference solution of desmopressin at 50 pg/mL, corresponding to a 100% 
recovery (0% matrix effect). 
3.5 Stability 
Urine samples fortified with desmopressin at 1 ng/mL were stored at room temperature and 
at -20°C. 3 mL specimens were collected after 0, 1, 2, 3, 4 and 5 days and stored at -20°C 
until analysis. 
3.6 Excretion studies 
Six urine samples from patients who received desmopressin were used in the study. Samples 
were obtained from the Department of Internal Medicine (Endocrinology) and Hematology 
of the Ghent University Hospital, with the approval of the Ethical Committee of the Ghent 
University (reference: B67020108809). Three patients received desmopressin intranasally (≈ 
10 µg/dose), two orally (200 µg) and one intravenously (20 µg). Samples were stored at -
20°C awaiting analysis. 
 
4 Results and discussion 
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4.1 Liquid chromatography 
Chromatographic separation was achieved by using a C18 column, which allowed 
satisfactory peak shapes and chromatographic retention for desmopressin, the internal 
standard and the carrier peptide. Using this column, a high percentage (90%) of ACN was 
required to elute desmopressin and the IS. The carrier peptide AVP that contains the 
terminal amino moiety eluted earlier (Figure 4.1). 
Different concentrations of HOAc and TFA acid in the aqueous and the organic mobile 
phases (from 0.01% to 1%) were tested during method development. The intensity of the 
chromatographic peak for desmopressin was higher in case of using 0.1% HOAc, 0.01% TFA 
for both the mobile phases.  
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Figure 4.1 Multiple reaction monitoring (MRM) extracted ion chromatograms for 
desmopressin of product ion at m/z 328.0 for desmopressin (parent ion at m/z 535.5), AVP 
(parent ion at m/z 542.7) and the internal standard (parent ion at m/z 520.8). 
4.2 MS/MS optimization 
The full scan mass spectrum of desmopressin exhibited an abundant [M + 2H]2+ ion (Figure 
4.2a), whereas the monocharged pseudomolecular ion [M + H]+ has approximately half of 
the intensity. Hence the double charged species was used as precursor to generate product 
ions. The product ion spectrum for this peptide showed several ions (Figure 4.2b) with good 
intensities (m/z 328.0, 120.0, 214.0, 276.1, 430.4 and 526.7). The origin of these fragments 
has been explained previously[12]. 
Two precursor-product ion transitions were selected for the MRM (m/z 328.0, 120.0 from 
parent ion m/z 535.5), according to the identification criteria for mass spectrometry-based 
qualitative assay recommended by WADA. For the IS and the carrier peptide only the most 
abundant transition was selected (respectively m/z 328.0 from parent ion m/z 542.7, and 
m/z 328.0 from parent ion m/z 520.8). However, the carrier peptide was not detected in the 
optimized method, due to the use of the divert valve. 
 
Figure 4.2 Desmopressin full scan MS (a) and product ion scan (b) of the parent ion [M + 
2H]2+. 
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4.3 Sample preparation 
 The majority of sample preparation protocols described in literature is optimized for 
immunoassays. Agersø at al.[9] successfully used SPE with octadecylsilyl cartridges as sample 
clean-up prior to radioimmunoassay. The procedure was based on previous work of Lundin 
et al.[7] who, in turn, adapted a method from Tausch et al.[16] for the detection of urinary 
AVP. 
Cation exchange columns have proven to be useful for the specific detection of 
desmopressin[12,13] and have proven to result in cleaner extracts than the octadecylsilyl 
cartridges.  Indeed, using the WCX cartridges protocol as a stand-alone sample preparation 
technique; the product ion at m/z 328.0 was detectable at 100 pg/mL.  Although, according 
to the WADA criteria for identification, one precursor-product ion pair is sufficient for 
identification, the use of two precursor-product ions is recommended. Unfortunately, the 
second most abundant ion at m/z 120.0 was highly interfered (Figure 4.3a). To obtain this 
latter transition with improved sensitivity and specificity, a further purification step was 
needed in addition to the WCX cartridge. Since these interferences were eluted from the 
SPE-column together with the desmopressin and coeluted during the chromatographic 
method also with desmopressin, they were considered to be from apolar origin. Hence, the 
use of an orthogonal technique was considered to eliminate these non-polar interferences 
and improve sample clean-up. A previous method for plasma delipidation without protein 
denaturation was adapted[17]. The adapted procedure consists of a liquid-liquid extraction of 
the lipids with a mixture of di-isopropyl ether:n-butanol 60:40 at a volume ratio of 2:1, pH 
5.2 and the other extraction was performed at pH 9.5 to remove both acidic and basic 
interferences. Due to the high pKa of the guanidine group in the arginine, desmopressin is in 
ionized form in the pH range used for the delipidation. Hence, desmopressin remains in the 
aqueous phase. 
Despite the fact that lipids are less abundant in urine than in plasma, a relevant effect was 
noticed, as presented in Figure 4.3b. The sample delipidated before SPE clearly showed a 
better signal for both transition compared to the same sample purified only with SPE. The 
increase in response for the product ion at m/z 328.0 was moderate but still relevant 
(approximately 30% as peak area and +50% as signal-to-noise ratio), whereas the quality of 
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the peak chromatogram was dramatically improved for the product ion at m/z 120.0, 
allowing to have an additional diagnostic ion, as recommended by WADA. 
Figure 4.3 MRM extracted ion chromatograms of the product ions at m/z 328.0 and m/z 
120.0 from the parent m/z 535.5 for a urine sample fortified with desmopressin at the 
limit of detection processed only with WCX cartridges and with the combination of 
delipidation and WCX. The effect on MS response and peak quality is evident, particularly 
for the less abundant fragment. 
4.4 Validation 
Validation was conducted using the optimized conditions.. Finally, the method showed an LOD of 
25 pg/mL, with signal to noise ratio greater than 3 for the two diagnostic transitions in all 
urine samples that were analyzed. Maximum tolerance windows (% of base peak m/z 328.0) 
were put ±10% (absolute) for m/z 120.0, according to the WADA identification criteria. 
The signals for the extracted diagnostic ions were not interfered at the retention time of 
desmopressin from the ten urine sample analyzed during method validation. The internal 
standard and the carrier peptide presented different retention time and did not generate 
any interference. 
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[deamino-Cys1, Val4, D-Arg8]-vasopressin showed to be an effective internal standard to 
control all the pre-analytical and analytical steps, with a sufficiently constant mass 
spectrometry response (RSD= 35.7%) and an absolute peak area >106 in all the samples 
analyzed. 
4.5 Extraction recovery and ion suppression  
MRM extracted ion chromatogram from a pure reference standard, a sample spiked prior to 
injection and a sample spiked before extraction were compared. According to the 
abundances recorded, the average extraction recovery of the preparation was estimated at 
59.3% (SD= 29.4). Signal reduction due to ion suppression in the ESI source was calculated as 
42.7% (SD= 12.9). 
4.6 Demopressin stability 
Desmopressin proved to be stable under freezing conditions in urine samples. At room 
temperature, however, some signs of degradation were noticed. After 5 days at room 
temperature, only approximately 80% of the initial dose was recovered. However, for the 
anti-doping framework storage at room temperature for such a period is not in agreement 
with the requirements set out in the International Standard for Laboratories[18]. Therefore 
this simulation experiment represents an extreme condition (worst-case scenario) that is not 
commonly present during routine sample handling. 
Additionally, the working solutions, stored at 4°C, showed optimal stability when compared 
after 1, 2 and 3 months with freshly made solutions. 
4.7 Method application 
As shown by the extracted ion chromatograms of product ions at m/z 328.0 and 120.0 in 
Figure 4.4, desmopressin was unambiguously detected in all urine samples collected after 
administration of the formulations summarized in Table 4.1. These findings confirm the work 
of Agersø et al.[9], which described urinary concentration of desmopressin higher than in 
plasma. No explanation for this high urinary excretion rate has been described so far, but the 
ionized guanidine/arginine moiety in the structure of the peptide might have an important 
role in increasing renal clearance. 
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Figure 4.4 MRM extracted ion chromatograms of the diagnostic product ions at m/z 328.0 
and m/z 120.0; desmopressin was unambiguously detected in urine after intravenous, oral 
and intranasal administration. No signal was registered in blank urine samples. 
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The high elimination rate from blood circulation of desmopressin and the low bioavailability 
of oral and intranasal formulations[9] were probably the main causes of the non-detection of 
this compound in plasma after oral and intra-nasal administration, as observed in our 
previous work[12]. In fact, as shown in the previous chapter, desmopressin was only 
detectable in plasma after intravenous administration. Urine sample collected from the 
same patients at the same post-administration time have revealed that urine must be 
considered the preferred detection matrix for doping control purposes, confirming the 
recent work of Thomas et al.[13]. 
Table 4.1 Summary of urine samples from excretion study, collected after administration 
of desmopressin via different routes 
 
 
5 Conclusions 
 
A reliable LC‐MS/MS method for detection of desmopressin in human urine has been 
successfully developed and validated. The method showed good sensitivity (LOD= 25 pg/mL), 
with the required specificity and selectivity.  
In particular, the use of the double (acidic/basic) delipidation step of the urine samples 
improved the performance of the method making it a promising tool to improve urine clean-
up for the urinary detection of other peptides as well. 
The results of the excretion studies demonstrate that urine is the preferred matrix for the 
detection of desmopressin abuse after oral, intra-nasal or intravenous administration.  
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1 Abstract 
 
Peptide hormones are becoming increasingly appealing to amateur and professional athletes 
as performance enhancing drugs. A particular aspect of this trend is represented by black 
markets, where a clandestine, uncontrolled trade of these substances takes place. Control of 
this phenomenon involves surveillance, public health and sport testing authorities. 
Several classes of peptides have reached the focus of being used as performance enhancing 
drugs: growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormone 
(GHRH) analogues, insulin-line growth factor 1 (IGF-1) analogues, mechano-growth factors 
(MGFs), growth hormone fragments (AOD9604), luteinizing hormone-releasing hormone 
(LHRH) agonists, and β-thymosins. 
Doping control analysis of these emerging drugs is a challenging task for laboratories. The 
numerous issues related to the misuse of black market peptides are analyzed here, including 
tools and strategies for identification of new peptide hormones, development of analytical 
methods and alternative models for pharmacokinetics (metabolism) studies, and public 
health issues. Finally, future perspectives for doping control laboratories are discussed. 
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2 Introduction 
 
Different classes of peptides with different pharmacological properties have become popular 
among elite and amateur athletes and bodybuilders for their performance-enhancing or 
masking properties or to improve physical appearance. Several of these prohibited 
substances, such as insulins and desmopressin, have received approval from regulatory 
agencies and are included in Section S2 of the WADA Prohibited List (“Peptide hormones, 
growth factors and related substances”). Those that have not been approved are prohibited 
regardless of their doping effect (Section S0)[1]. These formulations are not available in legal 
markets; nevertheless they are finding their way onto parallel, illegal channels of 
distribution. Such markets have long been dominated by steroids[2,3], but popularity of 
peptides is increased as demonstrated by the amount of seizures documented in the last 
years[4–7]. This phenomenon implies difficult challenges and new approaches for doping 
control laboratories. 
 
3 Black market peptides 
 
Doping control authorities and laboratories are currently facing an ever-evolving list of 
peptides coming from the black market. To the best of our knowledge, seven main classes 
have been described so far, according to pharmacological properties and structures (Table 
5.1).  For some of them, the doping effect is only theoretical and has not been demonstrated 
yet. The majority of them, including growth hormone releasing peptides (GHRPs), growth 
hormone releasing hormone analogues, insulin-line growth factor 1 (IGF-1) analogues, 
mechano-Growth factors, and AOD9604, acts on the GH/IGF-1 axis. 
Table 5.1 List of peptide classes  which are reportedly available in black markets. 
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GHRPs are the most investigated class of “small” prohibited peptides (molecular weight < 1.5 
kDa)[8–12]. GHRPs are synthetic analogues of met-enkephalin, a peptide with opioid effects, 
which stimulate GH synthesis and have no effect on the opioid receptor. Only GHRP-2 has 
received therapeutic approval, but it is available also as black market formulations[10,11]. It 
has been demonstrated that GHRP-2 can produce indirect GH doping which cannot be 
detected with the GH isoform differential immunoassay[13]. 
GHRH, also known as growth-hormone-releasing factor (GRF), is a 44 amino acid (AA) 
hypothalamic peptide that stimulates GH production and release. Analogues have been 
developed both on the basis of the intact peptide (tesamorelin)[14] and on the 1-29 fragment 
(sermorelin, CJC-1295 and CJC 1295)[15,16]. Moreover, a novel analogue of GHRH(1-44) with 
an unusual sequence has been identified in a confiscated vial in our laboratory (Chapter 7). 
IGF-1 (70 AA) mediates most of the anabolic effects of GH on protein metabolism, inhibiting 
protein breakdown and promoting protein synthesis. There are currently two approved 
preparations: Increlex (recombinant human IGF-1) and Iplex (IGF-1 bound to its binding 
protein IGFBP-3, but formulations containing IGF-1 and derivatives are also marketed 
illegally[2,17]. 
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MGF is a 24 AA splice variant of IGF-1 which is expressed in mechanically overloaded skeletal 
muscle[18–20]. Its role in muscle regeneration after exercise-induced damage has been 
demonstrated in vivo[21]. A C-term amidated MGF identified in confiscated material is 
described in this study (Chapter 6)[22]. Additionally, formulations containing a not better 
described PEGylated MGF appear to be available on Internet, but there is no description of 
this analogue in the literature, and so far no case of identification have been reported. 
The hexadecapeptide AOD9604 consists of the GH Fragment 177-191, modified with the 
addition of a tyrosine residue at the N-terminus. This portion of GH presents lipolytic action, 
and therefore AOD9604 has been investigated as anti-obesity drug[23]. Recently, it has been 
shown how this peptide does not affect the GH isoform immunoassay[24]. Furthermore, 
detection and in vitro metabolism have been recently investigated[25]. 
Pulsatile administration of luteinizing hormone-releasing hormone (LHRH) agonists may 
increase the secretion rate of luteinizing hormone and, consequently, testosterone[26,27]. 
Since LHRH has very short half-life, several analogues have been designed with AA 
substitutions at position 6 and/or 10[28]. Among these, Lupron (leuprolide), Synarel 
(nafarelin), Buserelin and Zoladex (goserelin) have received approval for treatment of 
prostatic cancer and pain associated with endometriosis[29]. LHRH and leuprolide have been 
identified in more than one case in a confiscated product by the Ghent Doping Control 
Laboratory (Table 5.2). 
TB-500 has been identified as the N-term acetylated 17-23 fragment of thymosin β4 
(Chapter 7), which corresponds to the actin-binding portion of the molecule and therefore it 
may as well have a role in tissue regeneration[30]. This compound is suspected to be used 
both in humans and in racehorses[31]. The intact form of thymosin β4 (44 AA) has also been 
reported. 
Finally, a cyclic peptide with potential doping effect, corresponding to the sequence 
cyclo[Arg-Lys-N(C6H9)Gln-Phe], has been identified, but there is no description in literature 
of the function or the effects of this molecule[32]. 
The peptides which were identified in DoCoLab in confiscated products during the last three 
years are listed in Table 5.2. The list contains also non-doping related peptides such as 
melanotan (a tanning agent) and thymo pentin (an immunostimulant). 
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Table 5.2 List of peptides identified by DoColab in confiscated products in the last three 
years. 
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4 From discovery to detection 
 
4.1 Identification of new peptides 
A fundamental role in the discovery of new unapproved peptidic drugs is played by the 
collaboration between laboratories and surveillance authorities, such as Custom Agency, as 
demonstrated by several case reports involving confiscated material, which have also 
received media attention[4,6,7]. Another important source of information is represented by 
internet markets, where peptides can be easily purchased with few clicks, and “underground 
literature” coming from websites such as bodybuilding forums. 
Identification of the active content of a black market formulation is the first step towards 
effective doping control analysis of a new doping agent. Several tools originally developed 
for large-scale proteomics studies have been used for the structural characterization of this 
type of molecules[33]. Particularly, liquid-chromatography coupled to high-resolution mass 
spectrometry (LC-HRMS) is the most used technique for this purpose, due to the possibility 
to obtain molecular mass of the compound via spectral deconvolution and to define the 
peptide sequence based on characteristic fragmentation pathways[34,35]. 
For small peptides, top-down approach is generally used[10,11,36]. With increasing the size of 
the peptide, bottom-up analysis including trypsin digestion can improve quality of the 
characterization[37], producing smaller peptides whose sequences can be combined to 
identify the molecule, as shown on Figure 5.1 for MGF. Although bigger proteins are not part 
of this study, it is worth mentioning that trypsin digestion is mandatory for identification of 
bigger proteins that ionize poorly when intact[38], and in case of glycosylated protein (e.g.: 
erythropoietins), enzymatic deglycosylation is also required[39]. For big proteins, sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is also an useful tool to 
establish molecular weight[38]. 
In a typical proteomics workflow, once the sequence has been elucidated, the identity of the 
protein/peptide can be confirmed by matching the observed sequence against sequence 
databases[40]. This can be applied also in the case of peptidic doping agents, especially if the 
identified peptide belongs to a newly discovered class of doping agents (e.g.: MGF[22]). 
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However, the creation of an internal database (containing sequences of native of digested 
analogues and constantly updated whenever a new species is identified) can significantly 
speed up the identification process in case of the discovery of new analogues of an already 
known class. 
 
Figure 5.1 Example of bottom-up identification (human MGF). 
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Since some peptides, such as GHRPs, have D-amino acid, nuclear magnetic resonance (NMR) 
analysis is recommended to elucidate completely the stereochemistry of the molecule[11,36]. 
The first reports on black market peptides are dated 2010 and describe the identification of 
GHRP-2[10], hexarelin[2], His-tagged IGF-1 LR3[2,17], and CJC-1295[37]. More recently, new cases 
were recorded, including the unknown cyclic peptide confiscated during a horserace 
event[32], C-term amidated mechano-growth factor[41] identified in an unknown vial, and TB-
500[36]. 
These papers already show the issues related to these cases: unlabelled or mislabelled 
vials[2,17,32,41], and presence of related impurities and/or unknown excipients[2]. From the 
point of view of doping control laboratories, the presence of non-characterized derivatives 
or impurities implies additional challenges for the development of effective LC-MS based 
methods. 
4.2 Analytical methods 
Since peptide hormones have generally very low plasma and urinary concentration (often in 
the femtomole range) and a short half-life (generally < < 1-2 days)[8,42], efficient testing of 
these substances is a difficult task, which becomes even more complicated in case of non-
approved drugs. In fact, pharmacokinetics (PK) studies, useful to characterize metabolism 
and excretion, are in this case limited by ethical constraints. In absence of PK data, it is also 
difficult to evaluate the fitness for purpose of an analytical method, especially in terms of 
limit of detection and detection window. Additionally, there is often lack of reference 
standard material in the market. On the other hand, custom peptide synthesis is currently 
available on the market at competitive prices; therefore laboratories have the possibility to 
obtain high-purity standards to use for their methods. 
Several LC-MS methods have been reported for the detection of peptides, which can be 
roughly divided according to the sample preparation strategies: solid-phase extraction 
(SPE)[12] and immunoaffinity purification (IAP)[43]. Urine is generally preferred to plasma for 
small peptides, because they tend to have longer detectability in urine (e.g.: 
desmopressin[44,45]). Nevertheless, as suggested by Thomas et al.[46], it could be particularly 
interesting to analyze plasma in the context of GH abuse, since the same serum samples 
collected for GH analysis could also be used to screen GHRPs. 
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IAP represents the technique of election for purification of bigger peptides (MW: 2-8 kDa). 
Several IAP-based methods have been developed both for plasma and urine, and they have 
been summarized in a review[43]. Among the peptide classes described in this review (which 
includes also methods for insulins and the synthetic ACTH analogue Synacthen®), detection 
of GHRH, LHRH and IGF-1 and analogues are described. Since MGF is a splice variant of IGF-1, 
they could theoretically be screened together, provided an antibody with reactivity for both 
peptides is used, but this has not been described so far. 
4.3 Metabolism studies 
Studying peptide metabolism can help improving their detectability, especially because the 
parent peptide usually is present in urine for a very limited time. Okano et al. have showed 
how detection of the AA 1-3 metabolite of GHRP-2 can increase the detection window for 
this peptide[8]. Additionally, recent MS technologies allow for untargeted full scan 
experiments and therefore to perform retrospective data analysis, and verify presence of 
metabolites in suspicious samples[12]. 
Since there is no possibility to perform administration studies on humans for unapproved 
peptides, several in vitro/in vivo models have been studied. A comprehensive study on 
metabolism of GHRPs has been published by Thomas et al.[46]. In this work, in vivo 
(administration in rats) and in vitro (incubation with human serum and recombinant 
amidase) models were used and then compared with the administration of GHRP-2 (the only 
approved drug of this class) in humans. Results yield to the discovery of two additional 
urinary metabolites (AA 1-3(Amide) and AA 1-6). Cox et al. used also serum to investigate in 
vitro metabolism of AOD9604[25]. Work from Ho et al. described use of homogenized horse 
liver to simulate the metabolism of TB-500 in the horse[31]. The use of human liver 
microsomes and liver and kidney S9 fraction for the metabolism of peptides has also been 
described recently, with results which are comparable to those obtained by Thomas et al. 
with in vitro models (see Chapter 8). 
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5 Black market as a problem of public health 
 
The trade of performance-enhancing substances represents a sub-market of the illegal drug 
market, a world-wide phenomenon that involves serious legal, economic, social and health 
issues[47,48]. 
Different (in some cases, overlapping) underground markets can be identified: 
- Counterfeit pharmaceutical drugs: used as low-cost generic drugs  
- Recreational drugs: both soft drugs (e.g.: marijuana) and hard drugs (e.g.: heroin) 
- Prescription drugs: abuse of controlled substances (e.g. depressants, stimulants) 
- Doping substances 
In terms of volumes and social impact[48], black market of performance-enhancing drugs may 
appear as a minor business and a minor social emergency. Nevertheless, it is clearly a 
problem of the utmost priority not only for doping control authorities. 
From the perspective of the Health Authorities, abuse of doping substances from black 
markets poses a significant risk to the health and safety of the users. Black market products 
are usually manufactured with no respect for meeting Good Manufacturing Practice (GMP) 
requirements[49,50]. A clear example of the absence of quality controls is described in Chapter 
7 of this study. These formulations lack certified quali-quantitative information, regardless of 
the approval of the active content for therapeutic treatment. 
Even when this information is correctly indicated, side effects can still be unpredictable in 
case of non-approved drugs. In fact these substances did not follow a standardized approval 
process, as in the case of approved formulations (e.g.: morphine) that are extensively 
studied, before and after their authorization, so that their pharmacokinetic and toxicological 
profiles are generally well known. Some of the side-effects caused by the abuse of ergogenic 
agents are well known[51], whereas some others are still to be investigated[52]. Numerous 
cases have been described particularly for anabolic steroids[53–55], EPO[56,57] and blood 
transfusions[58]. Concerning peptide hormones active on the GH/IGF-1 axis, their link with 
cancer is still to debate. Theoretically, GH/IGF-1 may provide an antiapoptotic environment 
 107 
 
that may favour survival of cancer cells, thus more studies are necessary to finally reject the 
risks. Continuous use of LHRH analogues can lead to hypogonadism and bone loss[59]. 
Though no cases related to use of black market peptides have been reported so far it is 
worth mentioning the peptide melanotan II. The use of this non-approved tanning agent, 
with no doping properties but also extremely popular on the internet markets, has been 
recently linked to arising of skin cancer[60]. 
Moreover, some of these peptides (e.g.: GHRP-2) were identified in products which were 
sold as “nutritional supplements”,as if they were not pharmaceutical drugs[10]. 
One of the most alarming cases was recently described by Walpurgis et al.[61], who detected 
an 18 kDa unknown fusion protein with no correlation to doping, but supposedly a product 
of an empty expression vector without the DNA insert of interest used for recombinant 
protein production. 
 
6 Conclusions and perspectives 
 
Black market peptides represent a growing threat to sports that must be approached at 
three different levels: the illegal trade, the risks for the health, and their use to cheat in 
sport. 
Collaboration between the different authorities has a crucial role in this battle: numerous 
efforts have already been put in the last years to increase awareness and to put limitations 
on this phenomenon, and to identify new potential doping substances, which is the first 
important step for monitoring the misuse in sports. 
Contemporarily, public health authorities have the important role to inform and educate the 
athletes not only on the immorality of cheating, but also on the risks of using these unsafe 
formulations, similarly as what has been done for other groups of substances. 
Concerning the work of doping control laboratory, the importance of preventing doping 
controls for these substances has been highlighted in the past[62]. As described in this 
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chapter, effective testing of these substances faces additional analytical issues, which are 
summarized in Figure 5.2. 
The studies performed in the last years have provided strategies and tools to face misuse of 
these peptides, including general strategies for identification, detection and development of 
alternative models to perform PK studies. Although it t would be interesting also to to study 
the effects of peptides with an unclear spectrum of action for a better understanding of their 
effectiveness as doping agents, similarly to what has been done for steroids[63]. 
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Figure 5.2 Summary of the issues related to doping control analysis of black market 
peptides. 
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Chapter 6 
Identification of a C-terminal amidated mechano 
growth factor (MGF) analogue in black market 
products. 
 
 
Adapted from: 
S. Esposito, K. Deventer, P. Van Eenoo. Characterization and identification of a C-terminal 
amidated mechano-growth factor (MGF) analogue in black market products. Rapid Comm. 
Mass. Spectr. 2012, 26, 686. 
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1 Abstract 
 
Mechano growth factor (MGF) is a splice variant of insulin-like growth factor that possesses 
anabolic properties and has not yet been approved for therapeutic use. Nevertheless, MGF is 
readily available on the black market. Although the World Anti-Doping Agency (WADA) 
banned the use of MGF in sports, no routinely performed methods have been reported for 
its detection. In this work, two preparations from the black market containing an unknown 
MGF analogue were characterized. 
Mass spectrometry characterizations of unknown preparations and reference human MGF 
were performed on Exactive Orbitrap® and triple quadrupole mass spectrometers after 
liquid chromatography. High accuracy measurements allowed direct matching of 
experimental spectra from full scan MS with data generated in silico, whereas low resolution 
full scan MS/MS provided further information on fragmentation. 
HCD scan of the analytes showed the presence of common b series fragments for black 
market preparations and human MGF reference standard, but all y series ions starting from 
(y1)
+ exhibited a difference of 1 Da in nominal mass. This difference was demonstrated to be 
due to a C-terminal amidation of MGF. High resolution data demonstrated that the products 
from black market were both identified as C-terminal amidated analogues of human MGF. 
Additionally, low resolution MS/MS characterization revealed a potentially diagnostic 
transition (m/z 717.8 → 431.1) for the detection of C-amidated MGF and discrimination from 
the endogenous form. 
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2 Introduction 
 
The use of peptide hormones with performance-enhancing properties is prohibited in sports. 
Consequently, these substances appear on the prohibited list issued by the World Anti-
Doping Agency (WADA) under paragraph S2[1].  
However, the availability of black market performance-enhancing products containing 
peptide hormones is increasing, as indicated in numerous recent publications[2–5]. 
Identification of these compounds is a first important step toward their detection in 
biological matrices[6]. 
One of the prohibited peptide hormones listed by WADA is human mechano-growth factor 
(MGF). Moreover, due to its hormonal properties MGF is prohibited by (inter)national 
regulations in many countries, including Belgium[7]. 
 MGF is a 24 amino acid peptide (sequence: YQPPSTNKNTKSQRRKGSTFEERK) also known as 
IGF-1Ec, generated from alternative splicing of the gene for insulin-like growth factor 1 (IGF-
1)[8]. 
Its structure, pharmacological properties, and expression of MGF-related genes have been 
extensively studied and described[9,10]. The potential misuse of MGF as a doping agent in 
sports has also been described[10–13]. Mechanical stimulation related to prolonged exercise 
and muscle damage up-regulates IGF-1 gene splicing, producing predominantly MGF. This 
MGF production has been mainly associated with anabolic processes including muscle 
growth and regeneration by activating muscle stem cells[9,14,15]. 
MGF has not yet been approved for any therapeutic use, and only preclinical studies have 
been reported[16,17]. Nevertheless, the bodybuilding literature on websites suggests that 
MGF is available as intramuscular formulations. 
Although WADA has already included MGFs in the Prohibited List, there is only anecdotal 
evidence of the misuse of this peptide hormone. No cases of the identification of MGF in 
black market products have yet been reported and no doping control method for its 
detection has been developed. 
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In order to focus attention both on the potential abuse of MGF and on the risks related to 
the low quality of black market products, the structural characterization of an MGF analogue 
in two black market products by ultra-high performance liquid chromatography/high-
resolution mass spectrometry (UHPLC/HRMS) and high-performance liquid 
chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS/MS) is 
presented here. 
 
3 Materials and methods 
 
3.1 Chemicals and reagents 
A reference standard of the human MGF was purchased from Phoenix Pharmaceuticals, Inc. 
(Belmont, CA, USA) and this will be further referred to as hMGF-R. 
Acetonitrile and water were purchased from BioSolve (Lexington, MA, USA). Glacial acetic 
acid was purchased from Merck (Darmstadt, Germany) and trifluoroacetic acid (TFA) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
3.2 Unknown black market products 
The first black market product containing MGF was confiscated by Belgian Customs during a 
routine control. The unlabeled, sealed vial contained approximately 10 mg of a white 
powder and this sample will be further referred to as MGF-C. 
The second black market product was bought from a website. The vial contained 
approximately 30 mg of white powder and presented the label ’Mechano Growth Factor -
IGF-13c – 2000 mcg - This product is for laboratory research purposes only. Can be harmful if 
used inappropriately. Keep out of reach of children’. This substance will be referred to as 
MGF-W. Both vials are shown in Figure 6.1. Stock solutions from lyophilized powder at a 
concentration of 10 mg/mL were prepared by dissolving the powder in aqueous acetic acid 
(2% v/v). Before MS experiments were carried out, the samples were diluted 1:100 with 
water/acetonitrile/acetic acid/TFA (95:5:0.1:0.01, v/v/v/v). 
 122 
 
 
Figure 6.1 Vials of MGF-C (left) and MGF-W (right). 
3.3 Liquid chromatography 
UHPLC separation was achieved with a Surveyor MS Pump Plus coupled with a Surveyor Plus 
autosampler (Thermo Scientific, Bremen, Germany) using a Poroshell 120 EC-C8 column (2.1 
50mm, 2.7 mm; Agilent Technologies, Böblingen, Germany). 
HPLC separation prior to low-resolution MS/MS was achieved with a Surveyor MS Pump Plus 
coupled with a Surveyor Plus autosampler using a Zorbax RX-C8 reverse phase column (2.1 
150 mm, 5.0 mm; Agilent Technologies, Santa Clara, CA, USA). For both UHPLC and HPLC 
experiments 30 µL were injected for each sample. The same binary gradient was used in 
both sets of experiments: mobile phase A consisted of water, 0.1% acetic acid, 0.01% TFA; 
and mobile phase B consisted of acetonitrile, 0.1% acetic acid, 0.01% TFA. Gradient elution 
started from 95% A for 1.5 min, decreased linearly to 0% A in 8.5 min, and was held at 0% A 
for 2 min. Finally, 95% A was eluted for 3 min to equilibrate the system, for a total run time 
of 15 min. A constant flow rate of 200 mL/min was maintained in both cases. 
3.4 High-resolution mass spectrometry 
Mass spectrometry characterizations of the black market products and the reference human 
MGF were performed on an Exactive benchtop, Orbitrap®-based mass spectrometer 
(Thermo Scientific), operating in positive ion full scan MS mode and higher-energy collision-
dissociation (HCD) scan mode at 50 eV. The sheath gas (N2) pressure was set to 60 (arbitrary 
units), the auxiliary gas (N2) pressure was set to 30 (arbitrary units) and the capillary 
temperature set to 350 °C. The capillary voltage and spray voltage were set to 30 Vand 3 kV, 
respectively. The instrument operated in full scan mode from m/z 100 to 2000 at 100 000 
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resolving power. Approximately 10 scans were averaged per spectrum. The automatic gain 
control (AGC) setting was 106. The data acquisition rate was 2 Hz. The Orbitrap performance 
was evaluated daily and, when required, external calibration was carried out with Exactive 
Calibration Kit solutions (from both Sigma-Aldrich and ABCR GmbH & Co. KG, Karlsruhe, 
Germany). 
3.5 Low-resolution MS/MS 
MS/MS characterization was performed on a TSQ Quantum Discovery Triple Stage 
Quadrupole Mass Spectrometer (Thermo Scientific, Bremen, Germany) equipped with an ESI 
source operating in positive mode The ESI–MS operating variables used in this study were as 
follows: capillary voltage, 3.5 kV; source temperature, 350 °C; sheat gas (nitrogen) pressure, 
30 psi; auxiliary gas (nitrogen) pressure, 10 psi; tube lens offset, 84V. 
3.6 Data analysis 
ProMass software from Thermo Fisher (Bremen, Germany) was used for spectral 
deconvolution. Protein Prospector[18] was used to compare and match acquired HCD spectra 
to theoretical spectra generated in silico. 
 
4 Results 
 
4.1 High resolution mass spectrometry 
In order to identify the active ingredients in the black market products, solutions of the 
MGF-C and MGF-W samples were injected for LC/HRMS analysis, together with hMGF-R. The 
chromatographic behavior of the three compounds was similar, with retention times within 
3.20–3.25 min. After full scan MS analysis, data deconvolution of the spectra of the three 
peptides provided charge state and molecular weight (MW) information on the compounds. 
The experimental MW of hMGF-R was 2866.4786 Da (mass error: 0.4 ppm), while the MWs 
of MGF-C and MGF-W were, respectively, 2865.4958 Da and 2865.4950 Da, both 
approximately 1 Da lower in nominal mass than the endogenous species. HCD scans of the 
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analytes at 50 eV, presented in Figure 6.2 and 6.3, and summarized in Table 6.1, showed the 
presence of several common product ions for all the three investigated peptides, including 
(b2)
+, (b21)
++, (b22)
++, (c1)
+, and the internal ion (SQRRK/KSQRR – NH3)
+. On the other hand, all 
y series ions that were detected for MGF-C and MGF-W exhibited a difference in the m/z 
value that corresponds to a 1 Da nominal mass also observed in the MW. First, substitution 
of an amino acid was considered. In silico generated fragmentation pathways allowed two 
hypotheses to explain the difference of 1 Da:  Substitution of Glu21 or Glu22 with either a Gln 
or a Lys. This substitution of Glu21 or Glu22 with a Gln or a Lys should lead to all the (y)
+, ions 
starting from (y3)
+ or (y4)
+, having a negative difference of 0.9839 or 0.9472 m/z units, 
respectively. However, the difference was observed for all the (y)+ product ions. Hence, it 
was concluded that a modification was already present in the (y1)
+. 
Modification of the C-terminus of peptides is a common strategy in pharmaceuticals to 
prolong the half-life of peptide drugs[19], and amidation is frequently used for this purpose. 
This modification causes a change in the nominal mass of the protein of -0.9839 Da, and the 
observed difference between the C-terminal Lys24 residue, with a theoretical m/z value of 
147.1128 for human MGF and 146.1289 for its postulated amidated version, was 0.9839. 
The presence of amidated Lys24 in the black market products was also confirmed 
experimentally by the presence of the product ion at m/z= 146.1288 (mass error: 0.4 ppm) in 
both MGF-C and MGF-W. The fragment corresponding to the amidated (y1)
+ was not 
detected in hMGF, that only exhibited the ion at m/z= 147.1129, (mass error: 0.5 ppm). 
Extracted ion chromatograms in Figure 6.4 clearly illustrate these findings. 
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Figure 6.2 High-resolution HCD spectra of human MGF (a) and isotopic pattern of its base 
peak [M + 3H](3+) (b), acquired at 50 eV. Product ions which are in common with those in 
the amidated analogue are in bold type. 
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Figure 6.3 High-resolution HCD spectra of C-terminal amidated MGF (a) and isotopic 
pattern of its base peak [M + 3H](3+) (b), acquired at 50 eV. Common product ions are in 
bold type.  
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Table 6.1 Mass spectrometric results for the structural characterization of MGF and for the 
qualitative identification of C-terminal amidated MGF from black market vials after HCD 
scan at 50 eV 
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Figure 6.4 Extracted ion chromatograms for the theoretical product ions (Amd y1)
+, m/z 
146.1288, and (y1)
+, m/z 147.1129, corresponding, respectively, to the amidated and non-
amidated C-terminal lysine. (Amd y1)
+ was detected both in MGF-C and MGF-W, whereas 
(y1)
+ was detected only in hMGF-R. 
4.2 Low-resolution MS/MS 
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Figure 6.5 shows MS/MS product ion spectra of hMGF (Figure 6.5a) and MGF-C (Figure 6.5b) 
from the precursor ion 717.8 ([M+4H]+4) recorded at 30 eV. The MGF-W spectrum is not 
presented, since it is identical to the one of MGF-C. Both spectra present several high 
abundant b and c product ions with the same nominal m/z values. Product ions 
corresponding to internal fragments or single aminoacids were also present. Three y ions of 
significant abundance were recorded: (y3)
+, (y22)
3+, and (y22-H2O)
3+. Among these, only the 
singly charged (y3)
+ ion exhibited a nominal difference of 1 m/z unit (m/z 432.2 for hMGF, 
m/z 431.1 for the C-amidated analogue) which allows a discrimination between the two 
forms. The extracted ion chromatogram (Figure 6.5c) shows that this product ion was 
detected only in the black market products. 
Therefore, the transition 717.8→ 431.1 can discriminate the C-amidated form from the 
endogenous using low resolution tandem mass spectrometry and, potentially, be used to 
detect MGF misuse in biological fluids. 
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Figure 6.5 Low-resolution full scan MS/MS spectra of product ions of hMGF (a) and MGF-W 
(b) from precursor ion m/z 717.8. MGF-C, not shown for brevity, as its spectrum is identical 
to that of MGF-W. The product ions (y3)
+, and (Amd y3)+ show a difference of 1 m/z unit 
and can be used to discriminate the two forms, as shown in the extracted ion 
chromatogram (c). 
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4.3 Detection of other ingredients 
The contents of the vials were also analyzed in order to detect anabolic steroids, and 
stimulants, using previously described methods[20–22]. None of these substances were 
detected. During full scan HR-MS analysis, mannitol was detected. Mannitol is an 
osmodiuretic agent also prohibited by WADA[23]. However, the low amount of mannitol 
present in the vials should not induce a significant diuretic effect and its presence is more 
likely to be related to its assistance during the lyophilization of the peptides[24]. 
 
5 Discussion 
 
Unlabeled, fake and/or wrong labeled vials are generally observed  for black market 
products[2,25,26]. 
The MGF-C vial did not have any labeling at all. The MGF-W vial exhibited a gross error on its 
label (IGF-13c instead of IGF-1Ec) and the amidation at the C-terminus is not mentioned. 
Hence, the difference between the declared active compound   and the real compound 
present in the black market product can have unpredictable consequences on biological and  
toxicological effects as well as on the detectability[26]. Hence, the described products are 
clearly illegal, both from a commercial and ethical point of view, but they also present a 
great risk for the health and safety of the consumers. 
In particular, these products (of doubtful quality) allow prices which are extremely low when 
compared with those from pharmaceutical companies. These prices make them very 
attractive for the customers. 
The seized vials are sold for intravenous, intramuscular or subcutaneous injections which 
may cause infections when not sterile. As mentioned in the Introduction, the biggest risk 
associated with human MGF is that it is not an approved drug and, in particular, the C-
terminal amidated version of MGF is not even described in the literature as a therapeutic 
candidate. Therefore, there are no toxicological studies, clinical trials or standardized 
protocols for the therapeutical use of the product in the black market vials. In most cases, 
internet suppliers are aware of these problems and to avoid claims they sell them frequently 
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with the advice ’intended for laboratory and research use only’. Although the products are 
officially sold as a research chemical and not for human consumption, the websites selling 
the products leave no doubt as to the intended purpose. Indeed, in some cases free syringes 
and bacteriostatic water are provided with the products. In the context of doping control 
analysis, these black market products cause great difficulties in their detection. In fact, small 
changes in the structure of a peptide (e.g. amidation of MGF) can have negative effects on 
their detectability, which is mostly based on mass spectrometric detection. 
 
6 Conclusions 
 
A C-terminal amidated analogue of human MGF was successfully identified in two black 
market products by means of LC/HRMS. This report demonstrates that further attention 
must be paid to such MGF preparations, in order to evaluate realistically its misuse in sport 
as a doping agent and the potential health dangers associated with low-quality 
manufactured black market products. Knowledge of the available products and their 
contents is required to develop efficient strategies for the detection of human MGF and its 
analogues in biological fluids doping control purposes. 
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1 Abstract 
In this work, a modified version of the 44 amino acid human growth hormone-releasing 
hormone (hGHRH(1-44)) containing an N-terminal proline extension, a valine residue in 
position 14, and a C-terminus amidation (sequence: 
PYADAIFTNSYRKVVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2) has been identified in a 
confiscated product by liquid chromatography-high resolution mass spectrometry (LC-
HRMS). Investigation of the product suggests also an incomplete C-term amidation. 
Similarly to other hGHRH analogues, available in black markets, this peptide can potentially 
be used as performance-enhancing drug due to its growth hormone releasing activity and 
therefore it should be considered as a prohibited substance in sport. Additionally, the 
presence of partially amidated molecule reveals the poor pharmaceutical quality of the 
preparation, an aspect which represents a big concern for public health as well. 
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2 Introduction 
The use of peptide-based doping agents has become increasingly popular during the last few 
years[1]. A relevant phenomenon for this class of substances is represented by unapproved 
peptide formulations[2–6]. According to the Prohibited List of substances and methods of the 
World Anti-Doping Agency (WADA)[7], any pharmacological substance without current 
approval by any governmental regulatory health authority for human therapeutic use, is 
prohibited. 
Unapproved drugs are generally not accessible through legal channels of distributions, but 
several cases have already demonstrated how they can find their way into black markets[2–
6,8,9]. This phenomenon represents a big concern for public health, since these preparations 
are often prepared with no respect for good manufacturing practice, with lack or even total 
absence of information on composition. Moreover, these peptides do not usually undergo a 
complete toxicological evaluation (e.g.: TB-500)[6], and therefore the risks associated with 
the intake are unpredictable. 
In sport drug testing, identification of new peptides with performing-enhancing properties is 
a first important step towards the development of effective detection methods for 
monitoring their misuse in sports[10,11]. In this context, collaboration between controlling 
authorities and laboratories has a crucial role in the battles against illegal trade of peptide 
hormones. 
Recently, an unknown preparation, consisting of an unlabeled vial containing lyophilized 
powder (Figure 7.1), was confiscated by Belgian Customs authorities and then delivered to 
our laboratory for identification. The product was characterized by ultra-high performance 
liquid chromatography/high-resolution mass spectrometry (UHPLC-HRMS). 
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Figure 7.1 The product confiscated by Belgian Customs. 
 
3 Materials and methods 
 
3.1 Chemicals and reagents 
Acetonitrile and water (LC grade) were purchased from BioSolve (Lexington MA, USA). 
Glacial acetic acid was purchased from Merck (Darmstadt, Germany). Formic acid was 
purchased from Fischer Scientific (Loughborough, UK). Sequencing Grade Modified Trypsin 
was purchased from Promega (Madison, WI, USA). Ammonium bicarbonate was purchased 
by Sigma-Aldrich (St. Louis, MI, USA) 
Stock solution of the unknown product was prepared by dissolving the content of the vial in 
water (1 mg/mL). For direct injection, sample was diluted 1:10 with 2% acetic acid. 
3.2 Trypsin digestion 
100 µL stock solution was evaporated to dryness (40 °C) and reconstituted in 200 µL trypsin 
solution (10 µg/mL in 25mM ammonium bicarbonate buffer, pH 8). Sample was incubated 
under gentle stirring for 24 hours at 37 °C. Trypsin digestion was stopped with 2% acetic acid 
(50 µL), and samples were then injected in the LC-MS system. 
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3.3 Liquid chromatography 
The UHPLC system consisted of an Accela LC (Thermo Scientific, Bremen, Germany) 
equipped with degasser, Accela 1250 pump, autosampler thermostated at 10°C and a 
heated column compartment. LC separation was performed using a Zorbax SB-C8, 2.1 x 50 
mm and 1.8 µm particle size from Agilent Technologies (Böblingen, Germany) thermostated 
at 25°C. The mobile phases were 0.2% formic acid in water (A) and 0.2% formic in 
acetonitrile (B). The gradient program was as follows: 100% A for 5 min, then decreased 
linearly to 0% in 8.0 min, and held at 0% for 2 min followed by an increase to the initial 
concentration of 100% A in 0.1 min. Equilibrium time was 5 min resulting in a total run time 
of 20 min. The flow rate was set constant at 250 µL/min and the injection volume was 10 µL.  
3.4 High-resolution mass spectrometry 
HRMS characterization was performed using a Q-Exactive benchtop, Orbitrap™-based mass 
spectrometer (Thermo Scientific, Bremen, Germany) operated in positive-negative polarity 
switching mode and equipped with a heated electrospray ion source (HESI). Nitrogen sheath 
gas flow rate and auxiliary gas were set at 60 and 30 (arbitrary units), respectively. The 
capillary temperature was 350°C, the spray voltage 3 kV or -3 kV and the capillary voltage 30 
V or -25 V, respectively in positive or negative ion modes. The instrument operated from m/z 
300 to 3 000 at 70 000 resolving power in full scan (FSMS). The automatic gain control (AGC) 
was set to 10e6. The data acquisition rate was 2 Hz. 
FSMS experiments were followed by targeted MS/MS (tMSMS) experiments at a normalized 
collision energy (NCE) set at 30% for peptide sequencing. For tMSMS experiments, the 
instrument operated from m/z 100 to 1 500 at 17 500 resolving power and AGC set to 10e6. 
Isolation window of the quadrupole was set to 3.0 m/z. The Orbitrap™ performances in both 
positive and negative ionization modes were evaluated daily and when it failed, external 
calibration was performed with Exactive Calibration Kit solutions (Sigma-Aldrich, and ABCR 
GmbH & Co. KG, Karlsruhe, Germany). A mass extraction window of 5 ppm was used. 
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3.5 Data analysis 
ProMass software from Thermo Fisher (Bremen, Germany) was used for spectral 
deconvolution. Protein Prospector v 5.10.19 was used to predict both trypsin digestion 
products and fragmentation of peptides for de novo sequencing[12]. 
 
4 Results 
 
4.1 Identification of  [Pro1, Val14]-hGHRH 
HRMS is an ideal tool for identification of peptidic compounds due to the possibility to 
determine the amino acid sequence of a peptide based upon its MS/MS spectrum. 
Preliminary analysis consisted of direct injection for FSMS analysis. Figure 7.2 shows full scan 
FSMS spectrum of the unknown compound, which presents a cluster of multicharged ions in 
positive mode (typical for peptides) in the m/z range 500-2000, whereby the six-fold charged 
ion at m/z 872.9687 is the most abundant. Mass spectrum deconvolution yielded a 
monoisotopic mass  5233.7555 Da. 
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Figure 7.2 Full scan spectrum of the unknown peptide. 
In order to obtain better peptide sequencing, the peptide was incubated with the proteolytic 
enzyme trypsin. Tryptic digestion allowed for the formation of smaller subunits of the 
peptide (MW < 2000 Da) which could be easily sequenced for the identification of the intact 
peptide. Tryptic product peptides that were identified are all summarized on Table 7.1. As 
shown in Figure 7.3 for six representative peptides, de novo sequencing from MS/MS 
spectra of tryptic products generated by enzymatic digestion of the native peptide provided 
identification of the unknown substance as a 46-AA modified version of human GHRH(1-44, 
corresponding to the sequence PYADAIFTNSYRKVVLGQLSARKLLQDIMSRQQGESNQERGARARL 
and to an exact monoisotopic mass of 5233,7637 Da, confirming the value obtained from 
spectral deconvolution of the native peptide. The peptide has a proline residue at the N–
terminus (Figure 7.3a and 7.3b), a valine residue in position 14 (Figure 7.3b and 7.3c) and a 
C-term amidation which are not present in hGHRH and it will be further referred as [Pro1, 
Val14]-hGHRH. 
The valine in position 14 was the most surprising finding, since it was inserted as an 
additional amino acid and not, as expected, in substitution of an amino acid (perhaps 
arginine or lysine, sensible to enzymatic degradation). On the other hand, N-terminal proline 
extension and C-terminal amidation have been described for GHRH analogues[13,14]. 
Cleavage sites for [Pro1, Val14]-hGHRH were the carboxyl side of Arg12,22,31,39,43, and Lys13,23, 
which are typical cleavage sites for trypsin. Digestion products with missing cleavages were 
also detected (due to incomplete digestion); however, these peptides provided further 
confirmation of the sequence. 
Table 7.1 List of tryptic peptides detected after digestion, including those with missing 
cleavages. 
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Figure 7.3 MS/MS spectra for six representative [Pro1, Val14]-hGHRH tryptic peptides.(b-
f). The C-terminus peptide ARL was detected mainly in the free form (see Figure 7.5).  
 
4.2 C-terminus: an incomplete amidation? 
Analysis of the tryptic products, particularly of the product AA 44-46, revealed the presence 
of both free and amidated C-terminus. As shown in Figure 7.4, beside the ARL-OH 
pseudomolecular ion (m/z=359.2394) (Figure 7.4a), the ion 358.2554 (Δm/z= -0.9840) 
(Figure 7.4b) corresponding to the amidated peptide ARL-NH2 (theoretical m/z=358.2561, 
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Δppm= -1.9) was detected. This result was confirmed by the detection of the two (y2-NH3)
+ 
ions at m/z= 270.1922 (Δppm= -1.1) (Figure 7.4c) m/z=271.1758 Δppm= -2.5) (Figure 7.4d). 
The ratio between the areas of the peaks indicates that the free peptide is significantly more 
abundant than the amidated. Unfortunately, no appropriate reference standards were 
available to provide a more precise determination. 
As trypsin does not have deamidating activity, the free form could not be generated during 
the digestion. Traces of the amidated form (monoisotopic mass= 5232.7560) were also 
detected in the native peptide (Figure 7.4e and 7.4f). 
Amidation, a common strategy to improve the pharmacokinetics properties of a peptidic 
drug, is generally performed in the last stages of the synthesis. Moreover, amidation is 
present in other GHRH analogues[4]. This finding suggests an incomplete amidation of the 
peptide during the manufacturing process. This is a clear example of the lack of quality 
controls typically associated to the production of black market peptides. 
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Figure 7.4 Extracted ion chromatograms and spectra of [M+H]+ and (y2-NH3)
+ ions from 
tMSMS of tryptic product AA 44-46 ARL-OH (precursor ion at m/z= 359.2401) (a,c) reveal 
the presence, in a minor amount, of 44-46 ARL-NH2 (b,d), most likely due to an low yield of 
the amidation during the synthesis of the peptide. Traces of the amidated peptides were 
also detected in the full scan spectrum of the native peptide (e,f). 
 
4.3 Misuse and detection of [Pro1, Val14]-hGHRH 
The human growth hormone-releasing hormone (GHRH) is a 44 amino acid hypothalamic 
peptide (sequence: YADAIFNTSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL) that 
stimulates GH production and release[14]. GHRH analogues are considered as prohibited 
substances according to section S2 of WADA List (peptide hormones, growth factors and 
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related substances)[7]. To the best of our knowledge, [Pro1, Val14]-hGHRH-NH2 has not been 
approved for any clinical application. 
There is reason to believe that [Pro1, Val14]-hGHRH might be marketed as performance-
enhancing drug. Indeed, similar to other several other analogues of GHRH(1-44) and 
GHRH(1-29) (tesamorelin, sermorelin, CJC-1293 and CJC-1295)[4], [Pro1,Val14]-hGHRH 
appears to find its way to black market and is classified by the marketers as a performance-
enhancing drug. GHRH analogues appear to be attractive especially to some communities 
such as bodybuilding and fitness. Obviously, no pharmacokinetics data are available for 
[Pro1, Val14]-hGHRH, but very low urinary and plasmatic concentrations (sub ng/mL) and 
short half-life can be expected. However, due to its similarity to other GHRH analogues, 
currently existing methods based on immunoaffinity purification followed by LC-MS 
detection should theoretically be able to monitor its abuse[11]. 
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Chapter 8 
Identification TB-500 in a black market product, 
in vitro metabolism and synthesis of reference 
standard material 
 
 
Adapted from: 
S. Esposito, K. Deventer, J. Goeman, J. Van der Eycken, P. Van Eenoo. Synthesis and 
characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified 
in TB-500, a product suspected to possess doping potential. Drug Test. Anal. 2012, 4 (9), 733-
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1  Abstract 
 
The product TB-500, which is suspected to be used as doping agent both in equestrian, 
canine and human sports, was confiscated by the Belgian Customs during a routine control. 
The composition of the formulation was not well defined, and therefore, in a first stage, a 
qualitative identification was needed in order to provide information for the development of 
analytical methods that can be used for monitoring TB-500 misuse. 
This work describes the detection and the identification of the active content of TB-500 by 
means of high-performance liquid chromatography/high resolution mass spectrometry using 
an Orbitrap Exactive benchtop mass spectrometer through a bottom-up approach. 
The N-terminal acetylated 17-23 fragment of human thymosin beta 4 (sequence: Ac-
LKKTETQ) was detected in the formulation. This peptide corresponds to the actin-binding 
domain of the human thymosin beta 4, which is known for promoting on tissue repair and 
angiogenesis. To unequivocally confirm the structure of the peptide, Ac-LKKTETQ was also 
synthesized by solid-phase peptide synthesis. The peptide was also analyzed by low 
resolution full scan MS/MS, in order to provide useful information on fragmentation 
behavior of the peptide. 
Additionally, in vitro metabolism studies were performed using human liver microsomes and 
S9 fraction in order to determine the most significant metabolites, which were synthesized 
as well. 
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2 Introduction 
 
The use of performance-enhancing peptides from black markets is a growing issue in 
human[1–4]  as well as equine sports drug testing[5]. 
A product called TB-500, claimed to increase muscle growth and tissue repair in horses and 
other mammals, is available on the internet and officially distributed. It is presented as “the 
synthetic peptide of the active region of thymosin beta 4 (Tβ4)”, without any further 
qualitative description such as amino acid sequence or molecular weight. Tβ4, a 43 amino 
acid peptide, is the most abundant member of beta thymosins[6]. Its primary function is to 
stimulate the production of T cells, which are an important part of the immune system. 
Additionally, Tβ4 has been shown to prevent apoptosis, promote cell survival, angiogenesis, 
and tissue regeneration in mice and rats[7]. 
TB-500 is intended for veterinary use only (10 mg/dose), but it is legitimate to suspect its use 
as doping agent not only in horse and greyhound racing, but even in humans. Indeed, TB-500 
packages, containing 6 powder vials and physiological saline solutions for injection, were 
already confiscated by officials to persons who declared that the product was for personal 
use. In at least one case this received also world-wide attention from the media since it was 
connected to a former professional athlete which was still employed by his team[8], while in 
another case, a former team doctor was arrested in the possession of the substance[9].  
These events suggest that TB-500 might also be used by athletes for doping purposes, 
although no evidence for a misuse has been reported so far. 
A preventive and proactive approach against these novel formulations containing peptidic 
drugs without any clinical approval is mandatory, including identification of the active 
content of these products, in order to monitor their misuse. Additionally, methods need to 
be developed for their detection and preferably, well characterized reference standards 
need to be synthetized. In this work, the active content of TB-500 was identified and 
synthesized. Moreover, three TB-500 metabolites were synthesized after in vitro 
experiments. 
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3 Materials and methods 
 
3.1 Chemicals and reagents 
All the reagents were analytical or HPLC grade. Reference standard of human Tβ4 was 
purchased from Bachem (Weil am Rhein, Germany). 
Acetonitrile, water, dichloromethane were purchased from BioSolve (Lexington MA, USA). 
Glacial acetic acid was purchased from Merck (Darmstadt, Germany); Methanol, formic acid, 
N,N'-diisopropylcarbodiimide (DIC), 4-dimethylaminopyridine (DMAP), N,N-
diisopropylethylamine (DIPEA), piperidine, pyridine, (methyl-t-butyl ether (MTBE), and acetic 
anhydride were purchased from Sigma-Aldrich (S. Louis, USA). 
All the fluorenylmethyloxycarbonyl chloride (Fmoc) protected amino acids were L-isomers. 
Fmoc-Lys(Boc)OH, Fmoc-Thr(tBu)OH, Fmoc-Glu(tBu)OH were purchased from Nova Biochem 
(San Diego, CA, USA). Fmoc-Leu-OH precoated WANG-Resin was purchased from Bachem. 
Fmoc-Gln(Trt)OH and O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU) from Iris Biotech GnBH (Marktredwitz, Germany). 
3.2 TB-500 
A TB-500 package, confiscated by Belgian Customs during a routine control, was delivered to 
the laboratory (Figure 8.1). The sealed vial contained approximately 10 mg of a white 
powder. Stock (1 mg/mL) and working solutions (100 µg/mL and 100 ng/mL) of TB-500 and 
human Tβ4 from lyophilized powders were prepared by dissolving them in aqueous acetic 
acid (2% v/v). 
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Figure 8.1 The package confiscated by the Customs containing six vials of TB-500 and saline 
solutions for injection. 
3.3 Liquid chromatography 
Chromatographic separation was achieved with a Surveyor MS Pump Plus coupled with a 
Surveyor Plus autosampler (Thermo Scientific, Bremen, Germany) using a Zorbax RX-C8 
reverse-phase column (2.1 x 150 mm, 5 µm) from Agilent Technologies (Santa Clara, USA). 
The conditions were the same for both high-resolution and low-resolution MS experiments. 
For each sample, 5 µL were injected. A binary gradient was used: mobile phase A consisted 
of water containing 0.2% formic acid; mobile phase B consisted of acetonitrile containing 
0.2% formic acid. Gradient elution was as follows: it started from 100% A for 5 minutes, then 
decreased linearly to 0% A in 10 minutes, and held at 0% A for 2 minutes. Finally, 95% A was 
eluted for 3 minutes to equilibrate the system for further injection experiments, for a total 
run time of 20 minutes. A constant flow rate of 300 µl/min was maintained. 
3.4 Mass spectrometry 
High-resolution mass spectrometry (HRMS) experiments were performed on an Exactive 
benchtop, Orbitrap-based mass spectrometer (Thermo Scientific, Bremen, Germany). The 
instrument operated both in positive full scan MS mode and positive higher-energy collision 
dissociation (HCD) “all ion fragmentation” MS/MS mode at 25 eV. The sheath gas (nitrogen) 
pressure was set to 60 (arbitrary units), the auxiliary gas (nitrogen) pressure set to 30 
(arbitrary units) and the capillary temperature set to 350°C. The capillary voltage and spray 
voltage were set to 30 V and 3 kV, respectively. The instrument operated in full scan mode 
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from m/z 100–2000 at 100,000 resolving power. The data acquisition rate was 1 Hz. 
Approximately 10 scans were averaged per spectrum. 
Low-resolution MS/MS characterization of TB-500 was performed on a TSQ Quantum 
Discovery Triple Stage Quadrupole Mass Spectrometer (Thermo Scientific, Bremen, 
Germany) equipped with an ESI source operating in positive mode The ESI–MS operating 
variables used in this study were as follows: capillary voltage, 3.5 kV; source temperature, 
350 °C; sheath gas (nitrogen) pressure, 30 psi; auxiliary gas (nitrogen) pressure, 10 psi; tube 
lens offset, 84V. 
3.5 Data analysis 
ProMass software from Thermo Fisher (Bremen, Germany) was used for spectral 
deconvolution. Protein Prospector[10] was used to compare and match acquired HCD spectra 
to those predicted in silico. Mass tolerance was set at 5 ppm. 
3.6 In vitro metabolism 
TB-500 was incubated both with human liver microsomes (HLM) and liver S9 fraction. These 
experiments are extensively described in Chapter 9. 
3.7 Synthesis of TB-500 and metabolites 
Ac-Tβ4(17-23) and its metabolites were synthesized using a standard Fmoc-SPS protocol[11]. 
 
4 Results 
 
4.1 HRMS identification of the active content of TB-500 
Solutions of TB-500 were first injected for HPLC-HRMS analysis in order to identify the active 
ingredient(s) in the formulation. Total ion chromatogram showed one main peak, which 
could be assigned to originate from a peptide-like structure at tr= 9.1 min. The full scan MS 
spectrum (data not shown) revealed the presence of two molecular ions of the same 
molecule, respectively 445.2532 ([M+2H]2+) and 889.4988 ([M+H]+). Spectrum deconvolution 
provided a molecular weight (MW) of 888.4910. It was immediately evident that TB-500 did 
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not contain the endogenous Tβ4 (MW: 4963.4642). Therefore, elucidation of the structure of 
the detected species was accomplished by de novo sequencing based on HCD of the peptide 
precursor at 25 eV. b+ and y+ ions allowed de novo sequencing of the peptide through direct 
matching with theoretical data. As shown in Figure 8.2a and summarized in Table 8.1, a 
heptapeptide was detected, corresponding to the 17-23 fragment of human Tβ4 (sequence: 
LKKTETQ). Additionally, all b+ ions showed a positive m/z shift of 42.0105 with respect to the 
Tβ4 fragment, indicating the presence of an acetylated N-terminus. The identified peptide 
(theoretical MW 888.4911) will be further referred to as Ac-Tβ4(17-23). Finally, a 
confirmation of the structure and the stereochemistry was given after synthesis of the “all L-
amino acid” peptide, as shown by the HCD spectrum depicted in Figure 8.2c, by comparison 
of respective NMR spectra in Figure 8.2b and 8.2d, and the chromatograms in Figure 8.3.  
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Figure 8.2 HCD MS/MS recorded at 20 eV (a) and 700 MHz-NMR (b) spectra of TB-500. The 
structure of the peptide was confirmed after synthesis of the Ac-Tb4(17-23), which 
presents identical MS/MS (c) and NMR (d) spectra. 
Table 8.1 Identification of Ac-Tb4(17-23) based on matching between the experimental 
and in silico data on b and y ions from HCD experiments. 
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Figure 8.3 TIC and base peak chromatogram for TB-500 (a, b), the synthesized Ac-Tb4(17-
23) (c, d), and Tb4 (e, f). 
4.2 Synthesis of reference standards 
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The absence of reference standards for most of the black market peptides, including Ac-
Tβ4(17-23), presents a problem in doping control concerning the fulfillment of compound 
identification criteria[12]. A major issue is the fact that mass spectrometry-based 
identification does not provide any indication on the stereochemistry of the amino acids in 
the unknown peptide. D-amino acids are commonly used to improve the pharmacokinetic 
profile of peptidic drugs by providing resistance to protease mediated degradation (e.g.: 
desmopressin) and thus it is not unlikely to find them in designer peptides. 
From the analytical point of view, different stereochemistry of a molecule can theoretically 
reflect in different chromatographic behavior and MS fragmentation. 
Therefore, synthesis of reference material is necessary both to provide essential identity 
confirmation of a new substance and as a quality control checks. 
Luckily, synthesis of small peptides is a relatively straightforward process. The most common 
method is represented by solid-phase synthesis (SPPS). In this technique, the peptide chain 
is assembled in a stepwise manner while it is attached at one end to a solid support. 
TB-500 was synthesized from the carbonyl group side (C-terminus) to amino group side (N-
terminus). The C-terminal glutamine was covalently bound to polystyrene beads (Wang 
resin). Once the first amino acid was activated by removing its Fmoc protecting group, the 
peptide is obtained by repeated cycles of coupling-deblocking (Figure 8.4). After all the 
amino acids were coupled, the peptide underwent acetylation. Finally, after completion of 
the synthesis the first amino acid is cleaved from the solid support. 
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Figure 8.4. Schematization of basic SPPS steps. 
After synthesis and before NMR analysis, the synthesized TB-500 was purified by preparative 
liquid-chromatography. Also the confiscated product underwent the same process in order 
to eliminate other components (excipients and possible impurities). As already shown in 
Figure 8.2b and 8.2d, NMR spectra confirmed TB-500 structure and stereochemistry. 
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4.3 In vitro metabolism studies and synthesis of TB-500 
metabolites 
The work from Ho et al.[13] showed that several TB-500 metabolites could be detected both 
in horse urine and plasma. Since TB-500 is a non-approved drug, administration studies on 
humans could not be carried out. Therefore, an investigation on TB-500 metabolism was 
performed using in vitro (human liver microsomes, S9 fraction, and fresh plasma) in order to 
evaluate the most probable metabolites. These models are extensively discussed in Chapter 
9. Similarly to Ho et al., a sequential cleavage from the C-terminus was recorded, whereas 
the N-terminus is  well protected by the acetyl group (Figure 8.7). 
 
 
Figure 8.5 Results from incubation of TB-500 in fresh serum. 
Finally, three metabolites were selected for synthesis and then implementation in routine 
analysis: Ac-LK, Ac-LKK and Ac-LKKTE. MS/MS spectra of these species are shown in Figure 
8.6. These metabolites are those which are detectable for the longest time in horse urine, 
and at the same time very abundant both in the in vitro models (roughly estimated by 
comparing absolute area of the peaks). The implementation of these metabolites in the 
routine methods (Chapter 10) will increase the chances to detect misuse of TB-500. 
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Figure 8.6 MS/MS spectra of the three synthesized TB-500 metabolites. 
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4.4 TB-500 and doping 
TB-500 is one of several formulations available on the online market that contain a peptidic 
drug which is claimed to enhance sport performances. Although it is marketed only for 
veterinary use it is sold to non-veterinarians as well via the internet and there is anecdotal 
evidence that is probably used by athletes.  
Ac-Tβ4(17-23) corresponds to the acetyl derivative of the major actin-binding site of Tβ4, 
that has been shown to promote angiogenesis, wound healing and hair growth in vitro and 
in animal models[14]. Therefore, the plausible rationale for use of TB-500 in doping lies in the 
role of Ac-Tβ4(17-23) in tissue growth and regeneration, which can be particularly important 
for recovery after intense workout or competition. The non-acetylated form of the peptide 
has been detected in vivo as an endogenous degradation product of Tβ4[14], whereas the 
acetylated form is not described. N-terminal acetylation is a common strategy in drug 
development of peptides to increase the half-life, and therefore the activity, of peptides[15]. 
This acetylation should allow for a clear differentiation between endogenous and exogenous 
Tβ4 in biological samples. 
Though there are no pharmacokinetics data on TB-500, urinary excretion can be expected as 
well as urinary concentration in the femtomole range, similarly to other peptides. 
Analysis of this peptide and its metabolites can be implemented in already existing methods 
for detection of small peptide hormones[16] (See Chapter 10). 
5 Conclusions 
 
Ac-Tβ4(17-23) was identified as the active content of the formulation TB-500. The identity 
was confirmed by synthesis of a reference standard. Moreover, three metabolites were also 
synthesized after in vitro metabolism studies. 
TB-500 must be considered a product with doping potential and its misuse should therefore 
be monitored by anti-doping laboratories. 
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Chapter 9 
In vitro models for metabolic studies of small 
peptide hormones in sport drug testing. 
 
 
Adapted from: 
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small peptide hormones in sport drug testing. J. Pept Sci. 2015, 21,1-9. 
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1 Abstract 
 
Peptide hormones represent an emerging class of potential doping agents. Detection of their 
misuse is difficult due to their short half-life in plasma and rapid elimination. Therefore, 
investigating their metabolism can improve detectability. Unfortunately, pharmacokinetic 
studies with human volunteers are often not allowed because of ethical constraints and 
therefore alternative models are needed. This study was performed in order to evaluate in 
vitro models (human liver microsomes and S9 fraction) for the prediction of the metabolism 
of peptidic doping agents and to compare them to the established models. The peptides 
which were investigated include desmopressin, TB-500, GHRP-2, GHRP-6, hexarelin, LHRH 
and leuprolide. Several metabolites were detected for each peptide after incubation with 
human liver microsomes, S9 fraction, and serum, which all showed endo- and exopeptidase 
activity.  In vitro models from different organs (liver versus kidney) were compared but no 
significant differences were recorded. Deamidation was not observed in any of the models 
and was therefore evaluated by incubation with α-chymotrypsin. 
In conclusion, in vitro models are useful tools for forensic and clinical analysts to detect 
peptidic metabolic markers in biological fluids.   
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2 Introduction 
 
In recent years, the number of approved peptide therapeutics has increased significantly[1]. 
Contemporarily, peptides have become increasingly popular among elite and amateur 
athletes and bodybuilders to enhance their sport performances or to improve physical 
appearance[2]. Several small peptides (molecular weight < 2 kDa) with different 
pharmacological properties have reached the focus of being misused[2,3]. 
Since peptide drugs only reach low plasma and urine concentrations (< 1 ng/mL) due to their 
short half-life (generally < 12-24 hours) and low therapeutic doses, efficient testing of 
peptide hormone use is a difficult task[4–7]. 
Characterization of the metabolism of peptides can help to improve their detectability; in 
particularly characterization of long-term metabolites can increase the detection window. 
Unfortunately several of these peptides (e.g.: TB-500) are not approved drugs and therefore 
excretion studies involving humans are limited by ethical constrains. Therefore, most of the 
research has focused on the detection of the parent drug[6,7]. However, metabolites of the 
growth hormone releasing peptide 2 (GRHP-2) (AA 1-3, AA- 1-3(Amide), and AA 1-6) have 
been detected in human urine, allowing to increase the detection window for this peptide. 
AA 1-3 was first detected by Okano et al.[8] and confirmed by Thomas et al.[9], whereas the 
other two metabolites were described by Thomas et al. in a comprehensive study on the 
metabolism of GHRPs using in vivo (administration in rats) and in vitro (human serum and 
recombinant amidase) models[10]. More recently, detection of the metabolite AA 5-9 of the 
luteinizing hormone-releasing hormone (LHRH) analogue leuprolide has also been 
described[11].  
The use of human liver microsomes (HLM) and/or S9 fraction for the metabolism of peptides 
has not been described so far, since these two models are generally used for small, non-
peptidic molecules which show prevalent hepatic metabolism[12]. 
In this work, we have evaluated and compared the use of in vitro models (HLM, liver/kidney 
S9 fraction fresh serum, and the deamidating enzyme α-chymotrypsin) for the prediction of 
metabolism of prohibited small peptides. Seven peptides among those prohibited by WADA 
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were chosen for this study (Table 9.1). All analyses were performed by liquid 
chromatography coupled to high-resolution mass spectrometry (LC-HRMS). 
Table 9.1 List of the peptides investigated in the study 
Peptide Amino acid sequence Abbreviation 
Pharmacologic/doping 
effect 
Desmopressin MrpYFQNCPdRG-NH2 
Mpa. 
Mercaptopropionic acid 
Haemodilution, with 
alteration of blood 
passport parameters 
TB-500 Ac-LKKTETQ   
Tissue regeneration, 
angiogenesis 
GHRP-2 dA(d-β-Nal)AWdFK-NH2 NaI: naphylalanine 
Increased growth 
hormone synthesis and 
secretion 
GHRP-6 HdWAWdFK-NH2   
Hexarelin H(dMethW)AWdFK-NH2 
MethW: 2-
methyltryptophan 
LHRH PyrHWSYGLRPG-NH2 Pyr: pyroglutami acid            
Et: ethyl group 
Increased testosterone 
synthesis and secretion 
Leuprolide PyrHWSYdLLRPG-NH(Et) 
 
3 Materials and methods 
 
3.1 Chemical and reagents 
Desmopressin, LHRH, leuprolide and GHRP-2 were purchased from Bachem Ltd. (Bubendorf, 
Switzerland). GHRP-2, GHRP-6 and hexarelin were a kind gift from the Australian National 
Measurement Institute, and were synthesized by Auspep (Tullamarine, Australia). TB-500 
was synthesized in-house (see Chapter 8)[13]. 
Peptide stock solutions (100 µg/mL) were prepared by dissolving the reference material in 
2% HOAc and stored at −15 °C. 
HPLC-grade water (H2O), acetonitrile (ACN) and methanol (MeOH) were purchased from 
Merck (Darmstadt, Germany). Formic acid (FA) was purchased from Fisher Scientific 
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(Loughborough, UK). Acetic acid (HOAc) and sodium acetate p.a. were of analytical grade 
and were purchased from Merck (Darmstadt, Germany).  
For in vitro incubations, phosphate buffer (pH 7.4), pooled human liver microsomes and liver 
S9 fraction, were from BD Bioscience (Erembodegem, Belgium). Kidney S9 fraction was 
purchased from (Lenexa, KS, USA). The gas used for mass spectrometry was nitrogen 
(Alphagaz2-grade) from Air Liquide (Desteldonk, Belgium). 
Plasma and serum samples were obtained from the Belgian Red-Cross and left over doping 
control samples from blood analysis. 
α-chymotrypsin (α-CT) from bovine pancreas was purchased from Sigma-Aldrich (Bornem, 
Belgium). 
3.2 In vitro model with microsomes and S9 fraction 
For microsomal incubation, 50 µL of each peptide stock solution were first evaporated to 
dryness at 40 °C. Dried standards were then reconstituted with 100 µL of 0.5 M phosphate 
buffer. 
The reaction was initiated by adding 2.6 µL of HLM or S9 fraction (both from human liver and 
kidney), to obtain a total enzyme protein concentration of 0.5 mg/mL. Cofactors (NADPH 
generating system) were not added, unlike in typical experiments with non-peptidic 
molecules, since they are essential for the CYP system, but not for proteolytic enzymes. 
The mixture was vortexed briefly and incubated at 37 °C for 6 h. To stop the incubation, 100 
µL of ice-cold methanol was added and the tubes were transferred to an ice-bath for 15 min, 
and the sample was then centrifuged for 5 min at 12,000 g at 4 °C. Finally, the supernatant 
was transferred to a low-bind Eppendorf vial, ready for LC-MS analysis. 
3.3 In vitro model with human serum 
50 µL of peptide stock solutions were evaporated, redissolved in 200 µL of fresh serum and 
incubated at 37 °C for 2, 4, 6 and 24 h. Solid-phase extraction (SPE) was used for purification 
and concentration of the compounds of interest; Oasis® HLB 3cc (60 mg) extraction 
cartridges from Waters (Milford, MA, USA) were used. The cartridge was first activated with 
2 mL of methanol and subsequently rinsed with 2 mL of water. Before loading, the sample 
was first diluted to 2 mL with water. After loading, the column was washed twice with 2 mL 
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of water. Then 1.2 mL of acetonitrile: water: formic acid (80: 15: 5) was used to elute the 
compounds from the column in a low-bind Eppendorf vial. After evaporation under a stream 
of oxygen-free nitrogen, the residue was redissolved in 100 µL of water/acetonitrile: formic 
acid (99:1:0.2 v/v/v) for LC–MS analysis. 
3.4 In vitro incubation with α-CT  
10 µl of peptide stock solutions were evaporated to dryness (40 °C) and then reconstituted 
in 100 µL α-CT solution (500 µg/mL in 25mM ammonium bicarbonate buffer, pH 8) in order 
to evaluate deamidation. Then, the sample was incubated under gentle stirring for 3 hours 
at 37 °C. Incubation was stopped with 2% acetic acid (100 µL) and samples were centrifuged 
and injected in the LC-MS system. 
3.5 LC-MS instrumentation 
Experiments were performed using a MS Pump Plus coupled with a Surveyor Plus 
autosampler (Thermo Scientific, Bremen, Germany). Separation was performed using a 
Zorbax 300SB-C18 reverse-phase column (1.0 mm×50 mm, 3.5 μm) from Agilent 
Technologies (Santa Clara, USA). The volume for injection was 10 µL. Mobile phase A was 0.2 
% formic acid in water, and mobile phase B was 0.2 % formic acid in acetonitrile. The 
gradient elution program was as follows: 99 % A for 5 min, then linearly changed to 0 % A 
over 10 min and held for 3 min. This was followed by a return to the initial conditions in 0.1 
min and equilibration for 6.9 min (total run time 25 min). The flow rate was constant at 50 
µL/min. 
MS detection was performed on a Q-Exactive mass spectrometer (hybrid triple quadrupole- 
Orbitrap mass spectrometer) from Thermo Scientific operating in positive mode. Full scan 
MS experiments were conducted for the first detection of metabolites, followed by MS/MS 
experiments of the most abundant molecular ions to confirm their structures. Conditions 
used were: sheath gas, 60 (arbitrary units); auxiliary gas, 30 (arbitrary units); capillary 
temperature, 350 °C; capillary voltage, 30 V; spray voltage, 4 kV; full-scan range, m/z 50–
1000; high-collision dissociation energy, 30 eV; resolving power, 140 000; data acquisition 
rate, 1 Hz. 
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MS/MS experiments were performed at different normalized collision energy (NCE) values 
for different metabolites in order to maximize information from the spectra. 
The online software Protein Prospector[14] was used for in silico prediction both of peptide 
metabolism and their fragmentation paths. In silico data were then compared with 
experimental results obtained by full scan MS and targeted MS/MS experiments. 
 
4 Results and discussion 
 
4.1 Metabolite characterization 
Peptides were first incubated with the different media, then samples were processed as 
described above and analyzed by LC-HRMS. Moreover, negative control samples containing 
only HLM or only S9 fraction were also prepared and analyzed. 
Metabolites were first identified in full scan MS experiments by extracting their exact m/z 
values of the pseudomolecular ions among those predicted in silico. Then, the identity of the 
metabolites was confirmed by targeted MS/MS experiments, as shown in Figure 9.1 for 
desmopressin (upper spectrum) and its metabolite AA 1-7 (lower spectrum).  
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Figure 9.1 MS/MS spectra of desmopressin (upper spectrum) and its metabolite AA 1-7 
(bottom) with a normalized collision energy (NCE)= 35.. 
 
Unspecific proteolysis via exopeptidases and endopeptidases was, as expected, the major 
metabolic pathway for peptides. Indeed, most common enzymatic degradation pathways for 
peptides involve cleavage of terminal amino acids (e.g. amino- and carboxypeptidases), 
which can break down peptides into monomers, and cleavage of non-terminal amino acids 
by endopeptidases (e.g. trypsin, chymotrypsin)[15]. 
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Preliminary experiments showed that production of metabolites from HLM and S9 fraction 
reached a plateau after 6 hours, whereas the best results in serum (in terms of number and 
peak area of the detected metabolites) were obtained when samples were incubated for 24 
hours (data not shown).  
Whereas the use of serum as an in vitro model has already been described[10] and the activity 
and abundance of serum proteases is well known, hepatic metabolism of peptides has not 
yet been intensively investigated. One of the reason may be the fact that peptidic drugs 
generally undergo very intense first-pass metabolism, both in the gastro-intestinal tract but 
also in the liver. Therefore, oral route is generally avoided[16]. 
 However, although the liver does not usually have a primary role in peptide metabolism, 
several classes of liver proteases have been described[16,17]. For example, mitochondrial 
proteolytic system has an important role in quality control of mitochondrial proteins, but it is 
legitimate to hypothesise that it can also catalyse (at least in vitro) degradation of peptidic 
drugs[17]. A few work have addressed hepatic metabolism of peptides: in vivo hepatic 
metabolism of insulin had been investigated[18], and homogenized horse liver was used for 
investigation of TB-500 metabolism in horse[19]. A complete list of the metabolites detected 
for all the investigated compounds in the different models is summarized in Table 9.2. As an 
example, chromatograms from GHRP-2 incubation experiments are shown in Figure 9.2. For 
completeness, results from preliminary experiments concerning incubation in plasma (blood 
was collected in EDTA tubes) are also shown. In general, results from incubation in plasma 
demonstrated very limited metabolization in this model. It is known, indeed, that EDTA 
tubes can limit proteolysis as already mentioned by Thomas et al.[10]. 
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Figure 9.2 Extracted ion chromatograms for GHRP-2 and four GHRP-2 metabolites analyzed 
after incubation with HLM, S9 fraction, serum, and plasma. 
 
Table 9.2 List of the metabolites identified for all the seven peptides with the different 
models. Mass accuracy was lower than 4 ppm in all cases. LHRH metabolism was 
investigated with both liver and kidney S9 fraction; the two models produced the same 
metabolites(*). 
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Desmopressin is a synthetic analogue of the antidiuretic hormone (ADH). The deamination 
on the cysteine in position 1, the use of D-Arginine in position 8, and the amidation of the 
carboxyl terminus were made with the purpose of protecting from enzymatic degradation 
and, thus, increasing half-life. Nevertheless, two metabolites were generated by cleavage at 
the carboxyl side of arginine and proline residues. Deamidation at the C-terminus was 
observed after incubation with α-CT (see further in the text). One of the metabolites 
Peptide Metabolite Theoretical m/z Charge HLM
S9 fraction 
(liver)
Serum In vivo [reference]
MrpYFQNCPRG-NH2 (parent) 535,2187 ++ D D D human [6,7]
MrpYFQNCPRG 535,7192 ++ ND
MrpYQNCPR 507,2120 ++ D D D ND
MrpYFQNCP 857,2916 ++ D D D ND
MrpYQNCPRG-NH2 (loss of Fby double cleavage) 461,1857 ++ D D D ND
Ac-LKKTETQ (parent) 445,2531 ++ D D D  horse [18]
Ac-LKKTET 381,2238 ++ D D D  horse [18]
Ac-LKKTE 330,7000 ++ D D D  horse [18]
Ac-LKKT 531,3501 + D D D  horse [18]
Ac-LKK 430,3024 + D D D  horse [18]
Ac-LK 302,2074 + D D D  horse [18]
dA(d‐β‐Nal)AWdFK‐NH2 (parent) 409,7210 ++ D D D rat, human [8,9,10]
dA(d‐β‐Nal)AWdFK 410,2198 ++ rat, human [10]
dA(d‐β‐Nal)A 358,1753 + D D D rat, human [10]
dA(d‐β‐Nal)A‐NH2 357,1801 + D D D rat, human [10]
(d‐β‐Nal)AWdFK‐NH2 374,2023 ++ D D D ND
AWdFK-NH2 550,3136 + D D D ND
WdFK-NH2 479,2765 + D D - ND
HdWAWdFK-NH2 (parent) 437,2296 ++ D D D rat [10]
HdWAWdFK 437,7216 ++ rat [10]
dWAWdFK-NH2 368,1924 ++ D D D rat [10]
dWAWdF 609,2823 + D D D rat [10]
AWdFK-NH2 550,3136 + D D D ND
WdFK-NH2 479,2765 + D D - ND
H(dMethW)AWdFK-NH2 (parent) 444,2374 ++ D D D rat [10]
H(dMethW)AWdFK 444,7293 ++ rat [10]
(dMethW)AWdFK-NH2 375,7079 ++ D D D rat [10]
AWdFK-NH2 550,3136 + D D D ND
WdFK-NH2 479,2765 + D D D ND
PyrHWSYGLRPG-NH2 (parent) 591,7914 ++ D D* D human [19]
PyrHWSYGLRPG 592,2910 ++ ND
HWSYGLRPG-NH2 536,2778 ++ D D* D ND
WSYGLRPG-NH2 467,7483 ++ D D* D ND
SYGLRPG-NH2 374,7087 ++ D D* D ND
YGLRPG-NH2 331,1926 ++ D D* D ND
GLRPG-NH2 498,3147 + D D* D ND
LRPG-NH2 441,2932 + D D* - ND
PyrHWSYGLRP 563,7727 ++ D D* - ND
PyrHWSYGLR 515,2463 ++ D D* - ND
PyrHWSYGL 437,1958 ++ D D* - ND
PyrHWSYG 380,6537 ++ D D* - ND
HWSYGLRP 508,2591 ++ D D* - ND
PyrHWSYdLLRP-NH(Et) (parent) 603,3307 ++ D D D human [11]
PyrHWSYdLLRP 591,804 ++ D D D ND
PyrHWSYdLLR 543,2776 ++ D D D ND
PyrHWSY 352,143 ++ D D D ND
PyrHW 453,1834 + D D D ND
HWSYdLLRP-NH(Et) 549,8153 ++ D D D ND
WSYdLLRP-NH(Et) 481,2858 ++ D D D ND
SYdLLRP-NH(Et) 388,2461 ++ D D D ND
YdLLRP-NH(Et) 344,7301 ++ D D D human [11]
dLLRP-NH(Et) 525,3896 + D D D ND
LRP-NH(Et) 412,3056 + D D D ND
SYdLLR 326,1949 ++ D D - ND
Desmopressin
detected after incubation 
detected after incubation 
detected after incubation 
detected after incubation 
Leuprolide
detected after incubation 
TB-500
Hexarelin
GHRP-6
GHRP-2
LHRH
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detected presents loss of phenylalanine by double cleavage. The formation of this species, 
catalysed by α-chymotrypsin, has been described previously[20]. 
TB-500 (N-term acetylated 17-23 fragment of thymosin β4) showed serial cleavage at the C-
terminus (see Chapter 8, Figure 8.5), whereas acetylation of the leucine seemed to provide 
efficient protection of the N-terminus. Results were similar to those described by Ho et al. in 
the horse using horse liver homogenate as in vitro model[19].  
Metabolism of GHRPs has been first investigated by Okano et al.[8] and then extensively 
described by Thomas et al.[9,10]. They observed action of amidases, oligopeptidases and both 
carboxy- and aminoexopeptidases after in vivo (administration to rats) and in vitro 
(incubation with human serum and recombinant amidase) experiments.  Then the 
incubation results were used and compared with the administration of GHRP-2 in humans. 
Results yielded the discovery of two additional human metabolites in urine (AA 1-3(Amide) 
and AA 1-6). After incubation of GHRP-2, GHRP-6 and hexarelin with human serum,  the 
metabolites detected were similar to those observed by  Thomas et al.[10], in a rat model and 
after administration to a human (only GHRP-2) [10]. It was also observed that the GHRPs 
metabolites were produced by HLM and S9 fraction. Moreover, additional metabolites were 
detected for GHRP-2 (3), GHRP-6 (2) and hexarelin (2) in all the three models in this study 
(Table 9.2). 
The other growth hormone secretagogues GHRP-1, GHRP4, GHRP-5, alexamorelin and 
ipamorelin could not be included in this study since no reference standards were available. 
All the substances mentioned so far were chemically modified analogues of endogenous 
peptides created with the aim of improving pharmacokinetic properties and, thus, 
therapeutic effect. All these peptides contain at least a modified amino acid that can provide 
unambiguous identification in the frame of sport drug testing. 
Other prohibited peptide drugs, such as LHRH, do not have modified AA, but their sequence 
corresponds to the endogenous hormones or to a portion of it. In this case, it is important to 
know whether they are present physiologically at detectable concentration in plasma or 
urine. LHRH is only secreted locally and it is not found in urine, as confirmed by the work of 
Thomas et al.[21]. 
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In this study, it was possible to verify how LHRH is indeed extensively metabolised by 
peptidases, showing serial cleavage both at the C- and N-terminus and also C-term 
deamidation. In vitro models showed a significantly higher number of LHRH metabolites 
compared to serum (Table 9.2). Since LRHR has very short half-life, several analogues (e.g. 
leuprolide) have been in fact designed with AA substitutions at position 6 and/or 10[22]. 
Leuprolide has both glycine residues in position 6 and 10 substituted respectively with a D-
leucine and an ethylamino moiety linked to the proline in position 9. A total of ten 
metabolites were identified in HLM and S9 fraction, whereas only nine were found in serum, 
as the metabolite AA 4-8 was not detected in this latter model. The metabolite AA 5-9 
described in vivo[23] was detected in all three models. 
4.2 Hepatic vs. renal in vitro models 
Kidneys are another main site for peptide metabolism. In particular, LHRH has been 
described as being extensively metabolised in kidney[23], and therefore it was used as model 
peptide for this investigation. LHRH was incubated with both liver and kidney S9 fraction for 
6h, with the same S9 protein concentration (final concentration of 0.5 mg/mL) and 
metabolites were then identified by LC-MS.  
No differences were noticed in the number of metabolites (summarized in Table 9.2). It is 
interesting to notice that for both models the sequential cleavages from C- and N-term 
stopped at the same site (the carboxyl side of the Gly5 residue). 
Thus, both for the liver and kidney models identical results for LHRH metabolism were 
obtained in our study. However, as a general rule, it is suggested to evaluate S9 fraction 
from different organs especially when a particular metabolism site is likely to have a main 
role. 
4.3 Deamidation 
Among the peptides investigated in this study, desmopressin, LHRH, GHRP-2, GHRP-6, and 
hexarelin have an amidated C-terminus. Deamidation results in a positive mass shift of 
+0.9852 Da. The mass shift of the deamidated metabolites is almost identical to that of the 
peak of the second isotope of the amidated species (mass shift +1.0046). Nevertheless, the 
two peaks have Δmass= 0.0194 corresponding to a Δppm= 38.8 (measured at 500 Da), and 
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can therefore be separated using a high resolution mass spectrometer with a resolving 
power > 25000, as shown in Figure 9.3. After incubation with HLM, S9 fraction and serum, 
the deamidated species was not detected for any of the peptides. Therefore this reaction 
was studied by using the enzyme α-CT, a protease with amidase activity. Deamidation was 
observed for all the five peptides after incubation with α-CT (Figure 9.4). 
 
Figure 9.3 Amidated (second isotope) and deamidated (first isotope) GHRP-2 MS peaks at 
resolution= 140 000. 
Thus, incubation with deamidating enzymes is preferred to HLM, S9 fraction and serum to 
evaluate deamidation. Deamidation of GHRPs was also described by Thomas et al.[10] by 
incubation with amidase. In that case, the GHRP-2 deamidated metabolite was also detected 
in human urine suggesting that C-term deamidation is a major degradation pathway for this 
peptide. This approach is less complex than the one used by Thomas et al.[10] to discriminate 
between the native and the deamidated peptide, since the method of Thomas et al.includes 
LC fractionation and evaluation of positive and negative response. 
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Figure 9.4 After incubation with α-CT, deamidation at the C-terminus was observed, as 
shown by extracted ion chromatograms for first (upper chromatogram) and second 
(middle row) isotopes of the molecular ions of the native peptide, and first isotope of the 
deamidated peptides (bottom). The latter was not detected in absence of the enzyme 
(control samples). 
4.4 Cost effectiveness of the different models 
Provided the access to fresh whole blood, serum is less expensive than S9 fraction and HLM. 
Moreover, incubation with serum is straightforward and doesn’t require use of other 
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(expensive) reagents. On the other hand, serum requires additional costs of the SPE-based 
sample preparation to purify the samples, whereas in vitro experiments require only 
centrifugation of the incubation solution to precipitate HLM/S9 corpuscolate. 
Purification of serum yields additional issues such as extraction recovery and interferences 
from a peptide-rich matrix. These interferences (e.g.: endogenous di-, tripeptides from 
serum which are identical to a portion of the sequence of the drug) could also generate, 
theoretically, false positive results in the detection of metabolites, which are less likely to 
occur with HLM and S9 fraction. 
 
5 Conclusions 
 
HLM and S9 fraction generated metabolites that were described in vitro (fresh serum) and in 
vivo (administration to human and rat model) in previous studies. Hence, HLM and S9 
fraction are not only a valid tool to study in vitro metabolism of small, non-peptidic drug, but 
also for small peptide hormones. However, none of the models is suitable for evaluation of 
deamidation: to this purpose, deamidating enzymes (e.g.: α-CT) must be used. Liver and 
kidney models produced the same metabolites: however, it is recommended to consider 
both for metabolism studies, particularly when information on main site of metabolization 
for a particular class of compound.  
In vitro models can potentially be used not only by the forensic analyst for the identification 
of better markers of doping with peptide hormones, but also by the clinical analysts as 
preliminary screening tools for the discovery of potential markers for peptides in biological 
fluids, especially plasma and urine. Moreover, they could be used in preclinical research 
during the screening process, in order to monitor metabolic stability of drug candidates, 
similarly to what is already being done for small molecules with “classic” in vitro models. 
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1 Abstract 
 
The final goal of the thesis was to implement analysis of small peptides in routine. To this 
purpose, a UHPLC-HRMS screening method was developed for the analysis of 31 small 
peptides, including desmopressin and two other vasopressin analogues, TB-500, 8 GHRPs, 
LHRH and 6 LHRH analogues, and AOD9604. The method includes also 3 TB-500 metabolites, 
5 GHRPs metabolites, and 3 LHRHs metabolites.  
Sample preparation consisted of solid-phase extraction with weak-cation exchange 
cartridges. Detection was achieved on a Orbitrap® Q-Exactive HRMS in targeted SIM mode 
monitoring peptide pseudomolecular ions. Contemporarily, full scan analysis was performed 
to allow retrospective analysis. The method was successfully validated, with limits of 
detection were in the range 20-500 pg/mL. The method uses only 1 mL of urine and allows 
for screening analysis of 25-30 samples per day. 
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2 Introduction 
 
As described in this thesis, the number and the variety of small peptide hormones which are 
subject of misuse in sport have grown exponentially in the last years. The list of small 
peptides and related metabolites) can currently count over 30 molecular entities (Table 
10.1). 
LHRH was the first compound whose detection has been investigated[1] as the pulsatile 
administration of this peptide can increase testosterone levels. Numerous LHRH agonists 
have been developed to improve pharmacological profile and are prohibited as well[2]. 
GHRPs, which are growth hormone secretagogues acting as synthetic ghrelin mimetics, 
represent the most investigated class of small peptidic doping agents, with numerous works 
describing their identification, detection and metabolism[3–7]. 
Desmopressin is the most representative synthetic analogue of arginine vasopressin (also 
known as antidiuretic hormone). It is considered a masking agents since it can artificially 
alter hematological parameters monitored in the framework of the biological passport[8].  
More recently, misuse of the thymosin beta 4 fragment TB-500[9] and the growth hormone 
fragment AOD9604 has been described[10]. 
Additionally, several metabolites have been described over the years for GHRPs[6], LHRH 
agonists[11], and TB-500 (see Chapter 9). Some additional metabolites were characterized in 
vitro during unpublished studies. 
Doping control laboratories have put a big effort on the analysis of this class of compounds. 
As a result of their work, general protocols for analytical methods, metabolic studies and 
synthesis of reference standard material have been established[3-13]. 
Although these peptides have different structures and properties, they share similar 
pharmacokinetics, analytical issues (e.g.: adsorption to surfaces), and chromatographic and 
mass spectrometric behavior. In a first phase, single-analyte or single-class methods were 
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published[1,4,12,13]. As the number of small prohibited peptides increased, the attention was 
focused on the development of multiclass methods. 
Table 10.1 List of small peptides and metabolites. 
 
 
Class Peptide Elemental composition Molecular mass
Desmopressin C46H64N14O12S2 1068,4269
Lys-vasopressin C46H65N13O12S2 1055,4317
Terlipressin C52H74N16O15S2 1226,4961
TB-500 C38 H69N10O14 889,4995
TB-500 M1 (1-2) C14H27N3O4 301,2001
TB-500 M2(1-3) C20H40N5O5 430,3029
TB-500 M3 (1-5)  C29H54N7O10 660,3932
GHRP-1 C51H62N12O7 954,4860
GHRP-2 C45H55N9O6 817,4721
GHRP-2 M1 (1-3) C19H23N3O4 357,1682
GHRP-4 C34H37N7O4 607,1292
GHRP-5 C43H46N8O6 770,3546
GHRP-6 C46H56N12O6 872,4445
GHRP-6 M1 (2-5) C34H36N6O5  608.2747
GHRP-6 M2 (2-6) C40H50N9O5 736,3934
Alexamorelin C50H63O7N13 957,4972
Ipamorelin C38H49N9O5 711,3851
Hexarelin C47H58N12O6 886,4607
Hexarelin M1 (1-3) C21H26N6O4 426,2003
Hexarelin M2 (2-5) C35H38N6O5 622,2903
LHRH C55H74N16O14 1181,4315
Leuprolide C59H84N16O12 1208,6455
Leuprolide M1 (5-9) C34H54N9O5 668,4248
Leuprolide M3 1(-3) C22H25N6O5 452,4703
Buserelin C60H86N16O13 1238,6560
Deslorelin C64H83N17O12 1281,6407
Goserelin C59H84N18O14 1268,6415
Nafarelin C66H83N17O13 1321,6356
Nafarelin M1 (5-10) C66H83N17O13 800,4334
Triptorelin C64H82N18O13 1310,6308
GH fragments AOD 9604 C78H123N23O23S2 1812,8588
AVP analogues
TB-500
GHRPs
LHRH agonists
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In 2012, Thomas et al. published a method for the determination in human urine of 11 small 
peptides, including desmopressin, LHRH and 9 GHRPs[5]. The method was based on WCX SPE 
purification and nanoLC-HRMS detection. The method showed the potential for allowing 
simultaneous analysis of chemically and pharmacologically unrelated small peptides. 
In this work, we have developed a comprehensive screening method for detection of small 
peptide hormones, expanding the array of substances to other peptides and classes, 
including other LHRH analogues, TB-500, AOD9604, and additional metabolites for a total 
number of 31 compounds, including 11 metabolites. Sample preparation was based on solid-
phase extraction (SPE), while detection was performed on a UHPLC-HRMS system. 
 
3 Materials and methods 
 
3.1 Chemicals and reagents 
All the chemicals and solvents used for sample pretreatment and chromatography were 
analytical grade or HPLC grade. Desmopressin was a kind gift from Ferring Pharmaceuticals 
(Malmö, Sweden). AVP and [deamino-Cys1, Val4, D-Arg8]-vasopressin were purchased from 
Sigma Aldrich (Saint Louis, USA). [Lys8]-vasopressin and terlipressin were purchased from 
Selleck Chemicals LLC (Houston, USA).  
All GHRPs, LHRH analogues and their metabolites were a kind gift from the Australian Sports 
Drug Testing Laboratory (Sydney, Australia) and were synthesized by Auspep. AOD9604 was 
a kind gift from the Centre for Preventive Doping Research, German Sport University 
(Cologne). TB-500 and its metabolites were synthesized in-house (see Chapter 9). 
Acetonitrile (ACN), water (H2O) and glacial acetic acid (HOAc) were purchased from JT Baker 
(Philipsburg, USA); methanol (MeOH) was purchased from Fisher Scientific (Aalst, Belgium); 
formic acid (FA) was purchased from Sigma-Aldrich. Sodium acetate was purchased by VWR 
International (Leuven, Belgium). 
Stock (100 µg/mL) and working solution (50 ng/mL) were all prepared using 2% HOAc 
aqueous solutions. 
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Internal standard (ISTD) solution contained [deamino-Cys1, Val4, D-Arg8]-vasopressin, 
13C,15N GHRP-2 metabolite (AA-1-3) and LHRH(2-10) at a concentration of 100 ng/mL in 2% 
HOAc. 
Only low binding microcentrifugal vials, type Eppendorf (Eppendorf, Hamburg, Germany) 
and low retention pipette tips (Sorenson Biosciences, Salt Lake City, USA) were used. 
3.2 Sample preparation 
Sample preparation was based on previous works[5,14]. Urine (1 mL) was spiked with 30 µl of 
ISTD solution. Then, 1 mL of acetate buffer (1M, pH 5.2) was added and the samples were 
centrifuged (4100 g, 10’, 20 °C). SPE purification was performed with Strata® X-CW (30 mg) 
cartridges, purchased from Phenomenex (Torrance, USA). The column was first activated 
with 1 mL of MeOH and then rinsed with 1 mL of H2O. After the sample was loaded, the 
column was washed first with 1 mL of H2O, then with 1 mL of 60: 40 H2O:MeOH mixture and 
1 mL MeOH. Finally, samples were eluted with 1.20 mL of  ACN: H2O: FA 80: 10: 10. The 
eluate was subsequently evaporated to dryness with a centrifugal evaporator (45°C, 240 g, 
1-2 h), and then dissolved in 120 µl of ACN: H2O: FA 99: 0.8: 0.2 prior to LC-MS analysis. 
3.3 Liquid chromatography 
The liquid chromatographic system consisted of an Accela LC (Thermo Scientific, Bremen, 
Germany) equipped with degasser, Accela 1250 UPLC pump, autosampler thermostated at 
10 ºC and a heated column compartment at 35 ºC.  
The LC separation was performed on a Agilent Zorbax RRHD C8 (50x2.1 mm, 1.8 μm) at a 
flow rate of 50 µL min-1. The aqueous solvent (A) consisted of 0.2% of FA in H2O, and the 
organic phase (B) was acetonitrile with 0.2% FA. The gradient started at 1 % B for 5 min, rose 
to 35 % B in 20 min, rose to 90 %B in 2 minutes and was followed by requilibration at 1 % B 
for 8 min, with a resulting overall runtime of 35 min. 
3.4 Mass spectrometry 
The LC effluent was pumped to an Q-Exactive benchtop quadrupole Orbitrap tandem mass 
spectrometer (Thermo Scientific, Bremen, Germany) operated in the positive mode and 
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equipped with an electrospray ionization (ESI) source. Nitrogen sheath gas flow rate and 
auxiliary gas were set at 60 and 30 (arbitrary units), respectively. The capillary temperature 
was 250 °C, the spray voltage 4 kV or -4 kV and the capillary voltage 30 V in positive or 
negative ion modes. The instrument operated both in full scan (FSMS) mode from m/z 300 
to 1200 and in targeted single ion monitoring (tSIM) at 70,000 resolving power. tSIM 
experiments were performed with an isolation window of 2.5 Da using an inclusion list with 
all target analytes. 
The automatic gain control (AGC) was 10e6. The Orbitrap performance in both positive and 
negative ionization modes was evaluated daily and external calibration of the mass 
spectrometer was realized with Exactive Calibration Kit solutions (Sigma–Aldrich, St. Louis, 
USA and ABCR GmbH & Co. KG, Karlsruhe, Germany). 
3.5 Method validation 
In accordance with Eurachem validation guidelines[15], 10 different blank human urine 
samples, were spiked at different levels (20, 50, 100, 500 pg/mL) to determine the limit of 
detection (LOD). The LOD was defined as the lowest level at which a compound could be 
identified in all 10 urine samples with one diagnostic pseudomolecular ion present with a 
signal-to-noise (S/N) ratio greater than 3 and a retention time difference of less than 0.2. 
Specificity was tested during the validation procedure. The 10 blank urine samples used for 
determining detection capability were extracted and analyzed as described above. 
To evaluate the extraction recovery, the 10 negative urine samples, used for the validation, 
were spiked with the peptides at 500 pg/mL and processed together with non-spiked urine 
samples. The extracts of the non-spiked urine samples were spiked after evaporation and 
before LC injection. After analysis the obtained peak areas of the two sets of samples were 
compared.  
Matrix effect was evaluated by comparing the peak areas of the urine samples spiked after 
extraction with a reference solution of peptides at 500 pg/mL, corresponding to a 100% 
recovery (0% matrix effect). 
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4 Results and discussion 
 
4.1 UHPLC-HRMS 
Analysis of peptides must have very low analytical LODs (in the femtomole range) in order to 
monitor the misuse of these substances for a realistic period of time. This requires the 
highest sensitivity allowed by the mass spectrometer. This assumption is based on the 
pharmacokinetic data currently available from excretion studies[3,13]. Other peptide such as 
TB-500, are expected to have similar behaviour, although no data on their metabolism are 
present, as excretion studies are limited by ethical constrains. 
The list of small peptides and related metabolites that can be monitored is constantly 
increasing, as methods are optimized and reference standard material becomes available. In 
fact, in the nanoLC-HRMS method published by Thomas et al. in 2012 eleven peptides 
(desmopressin, LHRH and 9 GHRPs) were included[5].  
The methods described in this work allow for the simultaneous analysis of a total of 31 
peptidic substances, including vasopressin analogues, LHRH agonists, GHRPs, TB-500, and 
AOD9604.  All the substances were detected at a concentration of 500 pg/mL or lower. 
The use of comprehensive and flexible methods is desirable in the field of doping control. 
These methods should have a generic sample preparation, untargeted detection and the 
possibility, in principle, to be extendable to other drugs. In the last few years, the availability 
of new instrument, particularly HRMS instrument, based on FSMS acquisition, has allowed 
the development of open screening methods with a virtually unlimited number of 
compounds, and the possibility to perform retrospective data analysis based on a posteriori 
hypothesis (preventive control analysis)[16,17]. 
The method was developed on a HRMS instrument, similarly to Thomas et al.[5]. 1 µg/mL 
solutions of the peptides were first injected in order to evaluate their MS behavior. FSMS 
experiments were first performed in order to evaluate the most abundant ion type. 
[M+2H]++ pseudomolecular ions were generally more abundant than [M+H]+  for the 
peptides, with a few exceptions. GHRP-4, GHRP-5 and most of the metabolites, with a lower 
molecular weight, showed prevalent monocharged ions (Figure 10.1), whereas the [M+3H]3+ 
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was the most abundant for AOD-9604, the biggest among the peptides included in this 
method (M.W. 1.8 kDa). 
. 
Figure 10.1 Full scan MS spectra of GHRP-2 and GHRP-2 metabolites (AA 1-3). 
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HRMS data typically show the isotopic pattern of the ions. This is useful in peptide analysis, 
since it provides additional information by assessing the charge of the ions. This can help the 
analyst to decide whether to proceed with confirmation of a suspicious sample. 
Theoretical m/z values of the most abundant species were calculated and then added in the 
inclusion list. The inclusion list (Table 10.1) contains all the m/z values which are monitored 
during tSIM experiments. The second isotope was selected for GHRP-1, leuprolide and 
goserelin because of a higher S/N ratio than the monoisotopic peak (italic in Table 10.1). 
Compared to FS, tSIM yielded lower LODs, but FSMS was also included in the method since it 
enables retrospective data evaluation for presently unknown peptides or metabolites. 
The use of multiplexed (MSX) option was enabled, with the possibility to acquire 10 tSIM 
experiments in the same scan event, allowing for the acquisition of a higher number of data 
points. However, the number of data points decreases with increasing the number of the 
ions in the inclusion list.  The use of detection windows (±2 minutes) and a long 
chromatographic runtime (35 minutes, the same as in the work from Thomas) for a better 
separation of the species (Figure 10.2), improved reproducibility and accuracy by detecting 
more data points across chromatographic peaks. 
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Figure 10.2 Extracted ion chromatogram from representative peptides of different classes 
detected at their LOD in tSIM mode and the internal standards. 
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4.2 Sample preparation 
As already stated, sample preparation is a critical issue for peptide analysis. Non-specific 
absorption on surface, variable recovery, loss of analyte during transfer and drying steps can 
cause poor or irreproducible results if adequate countermeasures, such as using low-bind 
plasticware and limiting the number of vial transfers, are not taken. 
Mechanism of retention/elution of mixed-mode SPE columns is based both on hydrophilic-
lipophilic balance and ion exchange. In our previous work on desmopressin, Oasis WCX® 
were successfully used, whereas Strata X-CW® were used in the method from Thomas et 
al.[5]. Other cartridges, including MM1® and MM2® from InterChrom, Oasis MCX® and Strata 
X-C® were evaluated, but they showed not adequate selectivity and/or recovery.  
The pH of the sample when loaded on the column was an important factor. The pH of urine 
can range from a low of 4.5-5 to a high of 8. pH values are also important for ion exchange 
interaction, since it determines whether the analyte or the resin is in the ionized or non-
ionized form. Different buffers were therefore tested, including formiate buffer (pH 3.8), 
acetate buffer (pH 5.2), phosphate buffer (pH 7) and carbonate buffer (pH 9.5). The best 
results were obtained with acetate buffer. The method uses only 1 mL of urine. Increasing 
the urine volume resulted in dirtier extracts which affected retention time stability. 
4.3 Validation 
No minimum required performance level (MRPL) values have been established so far by 
WADA for small peptides. However, according to the data available in literature for some of 
the peptides included in the method, a method for small peptides should be developed with 
the aim to reach sub-ng/mL detection for all the substances. 
 As shown in Table 10.2, detection was achieved for 26 out of 31 substances at 100 pg/mL or 
lower. This concentration can be considered a realistic minimum requested performance 
level (MRPL) value. However, alexamorelin, terlipressin and three short metabolites (TB-500 
M1 and M2, and leuprolide M2) could be detected only at 500 pg/mL, due to the presence of 
interferences or to low recoveries. As expected in a multiclass screening method, recoveries 
(10.8 to 125.0 %) and matrix effect (-48 to 65.0%) varied significantly. 
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Table 10.2 Validation data, including diagnostic ion, LOD, recovery and matrix effect for 
each peptide 
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5 Conclusions and perspectives 
 
A comprehensive UHPLC-HRMS screening method for the detection of 31 small peptide 
hormones (including 11 metabolites) in human urine has been successfully developed and 
validated. Detection was achieved at sub-nanogram levels for all the substances. Sample 
preparation times are limited 2-3 hours (less than 1 hour for SPE, 1-2 hours for evaporation), 
and 25-30 samples can be analyzed per day. 
It must be stated that this method cannot be used for confirmation analysis, as it is based on 
the detection of a single diagnostic ion, which is not sufficient to fulfill WADA criteria for 
qualitative identification in a confirmatory analysis[18]. Methods for confirmation of small 
peptide hormones, based on low resolution MS (triple quadrupole) are in part already 
available in our laboratory for several compounds (desmopressin, GHRPs and LHRH). As the 
development of confirmation methods for the rest of the peptides is still ongoing by the 
time this thesis is being written, this part was not included. 
Future studies will be focused on further improvements of method sensitivity, perhaps with 
the evaluation of the use of nanoLC system, as the LOD values of the method published by 
Thomas et al.[5] (which, on the other hand, included only 11 peptides from only three 
different classes) are at least 10-fold more sensitive than the one described here. According 
to the data already available in literature[1,3-5,13], small peptides generally reach very low 
urinary concentrations (lower than 100 pg/mL) in a few hours, making detection of their 
misuse difficult and confirmation even more complicated. This method is supposedly able to 
detect small peptides and their metabolites up to 1-2 days, which is a limited amount of time 
in the doping control context. The only exception is represented by desmopressin and its 
analogues, whose hemodilution effect last for only few hours[8]. For the other small peptides 
which exhibit mostly anabolic effects, prolonged detection and confirmation remain a big 
challenge. 
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This thesis described the implementation of the analysis of small peptide hormones in the 
Ghent Doping Control Laboratory. The topic has been tackled with an utmost comprehensive 
approach.  In fact, research has been conducted on all the aspects of the analysis, including 
1) investigation of the detectability of new substances (desmopressin), 2) identification of 
emerging peptide hormones with doping potential from illegal markets, 3) development of 
alternative in vitro models for the study of peptide metabolism and, finally, 4) 
implementation of comprehensive multi-class, multi-analyte screening and confirmation 
methods for detection of prohibited small peptides. 
 
1 Detection of desmopressin in plasma and urine 
 
In this first part, detection of desmopressin in human plasma and urine by LC‐MS/MS is 
described. In 2011, desmopressin was added by WADA to the Prohibited List as it can mask 
blood doping by altering blood parameter used in the framework of the Athlete Biological 
Passport[1]. Detectability was investigated both in plasma and urine, in order to determine 
which matrix allowed the longest detection window for the different administration routes 
(intravenous, oral, intra-nasal). 
In Chapter 3, the LC-MS/MS method for detection in plasma is described. Detection of the 
peptide in the biological matrix was achieved by LC-MS/MS (triple quadrupole), after protein 
precipitation, SPE with WCX cartridges, and HPLC separation. 
Detection of desmopressin in urine is described in Chapter 4. Same SPE protocol and LC-
MS/MS conditions were used. Additionally, a double (acidic/basic) delipidation step of the 
urine samples was used to obtain a better sample purification. 
The methods were both validated and showed good sensitivity (LOD= 50 pg/mL in plasma 
and 20 pg/mL in urine), with the required specificity and selectivity. 
Results of the excretion studies demonstrated that urine is the preferred matrix for the 
detection of desmopressin misuse in sport as it allows detection of the peptide after oral, 
intra-nasal or intravenous administration, whereas in plasma detection was possible only 
 217 
 
after intravenous administration. Results in urine were also confirmed by the work of 
Thomas et al.[2]. 
 
2 Black market of prohibited peptides 
 
In Chapter 5, the illegal trade of peptide hormones was discussed. This issue has become 
particularly relevant, as black markets appear as the main source for purchasing 
performance-enhancing peptides. Besides being clearly a threat to sport ethics, this 
phenomenon represents a big concern for public health as well. In fact, many unapproved 
drugs are marketed despite the risk associated to short and long term toxicity[3]. 
Furthermore, these products are manufactured without respect for GMP. 
In collaboration with Belgian Customs, the Ghent Doping Control Laboratory has analyzed 
and identified numerous confiscated products containing prohibited peptides/proteins of 
various molecular masses. Peptides were identified using high-resolution mass spectrometry 
using both top-down and bottom-up approaches. In particular, three peptides were 
identified for the first time (Chapter 6-8). 
In Chapter 6, a C-term amidated version of human MGF was identified in two different 
formulations. The first one was confiscated by the Belgian Customs, whereas the second was 
purchased from an online shop. Both vials lacked quali-quantitative information. MGF must 
be considered a potential doping agent, as MGF has a role in repair of muscle damage and 
other anabolic processes. 
In Chapter 7, the first identification of a new GHRH analogue with doping potential in a 
confiscated product was described. The 46 AA presented an unusual sequence, particularly 
for the presence of a valine residue in position 14. Moreover, the N-terminus was protected 
by degradation by the addition of a proline. The C-terminus of the peptide was amidated; 
however, analysis of the products from trypsin digestion revealed an incomplete amidation. 
This appears to be a clear sign of poor manufacturing quality, together with the absence of 
any label on the vial. 
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The characterization of TB-500, described in Chapter 8, was related to a case who received 
also relevant attention from the media, as involved a former cyclist was involved caught up 
in an investigation after Belgian custom officials intercepted a package containing the 
product. TB-500 is suspected to be used both for horse and human doping. The active 
content of TB-500 was identified as the N-term acetylated 17-23 fragment of the 44 AA 
peptide thymosin β4. After sequence identification by high-resolution mass spectrometry, 
the peptide was also synthesized to be used as reference standard material for the 
development of analytical methods. Furthermore, in vitro metabolic studies were 
performed, and three metabolites (Ac-LK, Ac-LKK and Ac-LKKTE) were also synthesized. 
The phenomenon of the black markets represents therefore a relevant, alarming aspect in 
the misuse of peptide hormones. From the analyst point of view, a continuous monitoring of 
these formulations is essential to identify new potential doping substances toward the 
implementation of dedicated analytical methods. This should be done in collaboration with 
Health and Control Authorities which are, in turn, responsible for the promotion and the 
execution of deterring policies. 
 
3 In vitro models for metabolic studies of small 
peptide hormones 
 
As shown in literature, monitoring peptide metabolites can provide a longer detection 
window than the parent compound[4]. However, excretion studies on unapproved peptides 
are strongly limited by ethical constraints. Therefore it was necessary to develop alternative 
in vitro models to perform metabolic studies. 
In Chapter 9, novel and established in vitro models for studying the metabolism of small 
peptides were evaluated and compared. In particular, the use of human microsomes and S9 
fraction for metabolic studies of peptides was described for the first time. So far, the use of 
these models was limited to “classic” small molecules, but both microsomes and S9 fractions 
demonstrated to be a valid tool for the identification of potential metabolites, providing 
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results comparable to previously described models (incubation with fresh serum)[5] in terms 
of number of metabolites that were identified. The advantages of using microsomes/S9 
fraction instead of fresh serum include a simpler sample preparation, fast incubation times 
and a limited amount of matrix interferences. The use of microsomes from different organs 
(liver and kidney) showed identical results. 
Additionally, deamidation was investigated using incubation with deamidating enzymes (α-
chymotrypsin), as neither incubation with microsomes/S9 fraction nor with fresh serum 
revealed the formation of these metabolites. 
All the metabolites that were described in literature as detected in vivo were also identified 
in the in vitro models. In conclusion, microsomes, S9 fraction and fresh serum are all useful  
tools not only for forensic, but also clinical analysts, to detect potential peptidic metabolic 
markers in biological fluids.   
 
4 Detection of small peptide hormones 
 
Finally, all the studies performed on desmopressin (Chapter 3 and 4), black market products 
(Chapter 5-8) and peptide metabolism (Chapter 9) found their natural conclusion in the 
development of a multi-analyte, multi-class UHPLC-HRMS method described in Chapter 10. 
In fact, the final goal of the thesis was the implementation in routine of the analysis of small 
peptide hormones in the laboratory. 
Sample preparation was based on weak cation exchange SPE, also described in other 
works[6,7]. An open screening method was developed on a UHPLC-HRMS system (Orbitrap® 
Q-Exactive), similarly in the 2012 work from Thomas et al.[6]. Detection was achieved in 
positive tSIM mode, monitoring one pseudomolecular ion for each peptide. Additionally, a 
positive FSMS spectrum was constantly acquired to allow for retrospective data evaluation. 
A total of 31 compounds, including 11 metabolites were included in both methods. Three 
different internal standards were used. Only 1 mL of urine was used. LODs were in the 
femtomole (sub-ng/mL) range for all the compounds. 
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5 General conclusions 
 
This thesis summarizes the effort that has been put by our laboratory in the last years to 
implement the analysis of small peptide hormones in routine, but also to contribute with 
research to increase the knowledge on the misuse and the analytical issues of this class of 
doping agents. Sample pretreatment strategies appear well defined, with the use of SPE. In 
this area, it is possible to expect improvements in sample throughput capabilities.  
On the other hand, there is still room for improvements in the detection capabilities, in 
order to increase detection and confirmation windows. Both low-resolution (triple 
quadrupole technology) and high-resolution (Orbitrap® technology) were used in this thesis. 
In particular, the first was used for the detection of desmopressin in plasma and urine, 
whereas the multianalyte screening method was developed on the HRMS instrument. 
Although a direct comparison was not made in this work, both technologies show 
advantages and disadvantages in their application to doping control analysis of small 
peptides. 
The measured LODs for desmopressin in urine are similar(25 pg/mL versus 50 pg/mL). 
However, the method described in Chapter 4 can be used for confirmation analysis, since 
two MRM transitions were validated at the method LOD. The HRMS method (Chapter 10) 
uses only one transition, based on the tSIM detection of the pseudomolecolar ion and 
therefore it can only be used for screening. On the other hand, this acquisition mode 
provides accurate mass data and  information on the isotopic cluster of the ion. At the same 
time, full scan acquisition allows for retrospective analysis and fast implementation of new 
peptides. For this reason, it represents a valid choice for screening analysis. 
MSMS experiments on the HRMS instruments (targeted MSMS and data-dependent MSMS) 
were also performed, but the method did not show adequate LOD (data not shown). So far, 
there is only one work that describes sensitive detection of a small peptide (desmopressin) 
using HRMS[2]. Further improvements are still needed in order to implement routine use of 
HRMS for confirmation analysis of small peptides.  
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Future research on small peptides will be oriented mainly in the optimization of methods. 
Sensitivity remains the top priority for this analysis, due to the short detection window for 
these substances. Improvements in this direction can be obtained taking advantage of 
technologic advances (new LC-MS systems or better purification strategies) and 
characterization of additional long-term metabolites. Moreover, there is room for improving 
time- and cost-effectiveness of methods. 
The first method describing detection of a single, small peptide (LHRH) has been published in 
2008[8]. Since then, significant progresses have been made thanks to the research performed 
by WADA laboratories. Thanks to all this work, protocols for the development of detection 
methods, metabolic studies and identification of new peptidic doping agents have been 
established.  
At the same time, the research has contributed to increase WADA awareness on the topic. 
Therefore, it is expected that a work of harmonization will be done, providing adequate 
qualitative (dedicated identification criteria) and quantitative (MRPL) parameters. 
In conclusion, it is legitimate to predict that the majority of the laboratories will implement 
analysis of small peptides in the next few years, similarly to what has been done for other 
classes in the past, and thus marking another step forward in the fight against doping. 
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Het onderwerp ‘kleine peptide-hormonen’ werd in al z’n facetten onderzocht. In een eerste 
deel van de thesis wordt de analyse van een klinisch relevante substantie (desmopressine) 
onderzocht. Het tweede deel spitst zich toe op de identificatie van illegale preparaten die 
peptide-hormonen bevatten. In een derde deel wordt een in vitro-model besproken om 
metabolisatie van peptide-hormonen te onderzoeken. In het vierde, en laatste, deel wordt 
de ontwikkeling en validatie beschreven van een methode om peptide-hormonen 
routinematig op te sporen in urine. 
 
1 Detectie van desmopressine in plasma en urine 
 
In dit  deel van de thesis werd de detectie van desmopressine in humaan plasma en urine 
met behulp van LC-MS/MS beschreven. Desmopressine is een klinisch relevant peptide en 
wordt gebruikt in de behandeling van o.a. enuresis nocturna. In 2011, werd desmopressine 
toegevoegd aan de verboden lijst van WADA omdat desmopressine het opsporen van 
bloeddoping kan bemoeilijken. Dit is belangrijk in het kader van het biologisch paspoort[1]. 
Zowel in plasma als in urine werd de detecteerbaarheid onderzocht. Dit had tot doel om te 
bepalen welke matrix het meest geschikt is om de verschillende administratie-routes te 
detecteren.  
In hoofdstuk 3 wordt de detectie in plasma beschreven. Om de plamsa-stalen op te zuiveren 
werd er eerst een proteïne-precipitatie uitgevoerd, gevolgd door een vaste-fase-extractie 
met zwakke kationen-uitwisselaar (type WCX). Finale detectie van het peptide werd 
bekomen met behulp van  LC-MS/MS. 
De detectie van desmopressine in urine wordt beschreven in hoofdstuk 4. Dezelfde vaste 
fase extractie-strategie en detectie methode werd gevolgd als bij de plasma-experimenten. 
Bijkomend werd een dubbele (zuur/base) delipidatie stap ingevoerd om de urinestalen extra 
op te zuiveren. 
Zowel de detectie in urine als  in plasma werd gevalideerd. In plasma werd een detectiegrens 
(LOD) bekomen van 50 pg/mL. In urine kon detectie van desmopressine gevalideerd worden 
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tot op 20 pg/mL. Er werd ook voldaan aan de vooropgestelde specificiteit  en selectiviteit. De 
resultaten zijn in overeenstemming met  het werk van Thomas et al.[2]. 
De excretiestudies tonen aan dat urine de  preferentiële matrix is om sport-gerelateerd 
desmopressine misbruik op te sporen. Bij alle onderzochte administratieroutes (oraal, 
intraveneus en intranasaal) kon desmopressine gedetecteerd worden. In plasma kon 
desmopressine enkel gedetecteerd worden na intraveneuze toedieningswegen. 
 
2 Illegale handel van kleine peptide-hormonen.  
 
In hoofdstuk 5 wordt de illegale handel van peptide-hormonen beschreven.  De illegale 
handel van peptide-hormonen is in een hogere versnelling gekomen door de 
beschikbaarheid van het internet. Dit medium laat toe om volstrekt anoniem, illegale 
producten aan te kopen. Niet alleen vervalst het gebruik van deze peptide-hormonen  
sportprestaties, ze vormen ook een bedreiging voor de volksgezondheid aangezien de 
toxiciteit van deze substanties onbekend is[3]. Bovendien worden deze substanties 
vervaardigd in niet traceerbare industrieën, waardoor enige vorm van kwaliteitsborging 
(GMP) ontbreekt. DoCoLab heeft in samenwerking met de douane, verschillende illegale 
preparaten onderzocht die mogelijks verboden peptide-hormonen bevatten. Dit onderzoek 
leidde tot de identificatie van 3 nieuwe peptide-hormonen. De peptides werden 
geïdentificeerd met hogeresolutiemassaspectrometrie met zowel “top-down” als “bottom-
up” approach (hoofdstuk 6-8).  
In hoofdstuk 6 wordt de identificatie van een geamideerde (C-terminus) versie van het 
humane MGF besproken. MGF moet beschouwd worden als een dopeermiddel aangezien 
MGF een rol speelt bij het herstellen van spierweefsel en betrokken is bij verschillende 
anabole processen in het menselijke lichaam. 
Dit peptide werd teruggevonden in twee verschillende preparaten. Het eerste preparaat 
werd in beslag genomen door de Belgische douane en het tweede preparaat werd 
aangekocht via internet. Voor beide preparaten ontbrak elke vorm van kwaliteitsgarantie.  
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In hoodstuk 7 wordt de detectie en identificatie van een GHRH-analoog besproken. Dit 
peptide-hormoon werd ook teruggevonden in een geconfisqueerd product. 
Het peptide-hormoon bestaat uit 46 aminozuren, en heeft een abnormale sequentie, 
aangezien op positie 14 een valine-aminozuur is ingebouwd. Bovendien is de  N-terminus 
beschermd tegen degradatie door toevoeging van het aminozuur proline. Bovendien was de 
C-terminus van het peptide geamideerd. Naast het geamideerde peptide werd er in het 
geconfisqueerd product ook niet geamideerd-peptide gedetecteerd. Dit wijst op een 
incomplete amidatie en is nogmaals een bewijs voor de ongecontroleerde productie en de 
afwezigheid van enige kwaliteitsborging.  
De karakterisatie van TB-500 is beschreven in hoofdstuk 8 en kreeg heel wat media aandacht 
omdat een voormalige wielrenner dit preparaat aankocht via het internet. 
Van TB-500 wordt verondersteld dat het gebruikt wordt voor zowel humane als 
paardendoping. De actieve component van TB-500 werd geïdentificeerd als het N-terminaal 
geacetyleerde fragment 17-23 van het, uit 44 aminozuren bestaande, peptide-hormoon 
thymosine β4. Na identificatie van de aminozuur-sequentie mbv hoge resolutie 
massaspectrometrie, werd het peptide ook gesynthetiseerd. Het gesynthetiseerde product 
kan gebruikt worden als referentie standaard om analytische methodes, voor de detectie 
van TB-500, op punt te stellen. Bijkomend werden, in het kader van een WADA-project, 3 
metabolieten gesynthetiseerd (Ac-LK, Ac-LKK and Ac-LKKTE). Het bestaan van deze 
metabolieten  werd mbv een in vitro model vastgesteld. 
Er kan besloten worden dat het fenomeen van de “zwarte-internet- markt” een relevant en 
alarmerend probleem is. Daarom is het belangrijk dat laboratoria verantwoordelijk voor 
volksgezondheid deze nieuwe preparaten, die te koop worden aangeboden, controleert op 
de aanwezigheid van nieuwe illegale peptides. Dit onderzoek kan enkel verlopen in nauwe 
samenwerking met  douane en andere federale instellingen die de producten in beslag 
kunnen nemen. 
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3  In vitro modellen voor metabole studies van kleine 
peptide-hormonen 
 
Peptide-hormonen worden snel gemetaboliseerd. Daarom kan het monitoren van 
metabolieten het detectievenster verlengen[4]. Om de metabolisatie te onderzoeken dient 
het peptide-hormoon toegediend te worden aan gezonde vrijwilligers. Aangezien  de 
toxiciteit van deze illegale peptide-hormonen niet gekend is,  kunnen ze ook niet toegediend 
worden aan vrijwilligers om ethische redenen.  
In hoofdstuk 9 worden alternatieve modellen om de metabolisatie te onderzoeken, 
voorgesteld en vergeleken. In het bijzonder het gebruik van humane microsomen en S9-
fracties wordt voor de eerste maal beschreven in het kader van peptide-metabolisatie. Tot 
op heden werd het gebruik van microsomen en S9-fracties enkel beschreven om 
metabolisatie van kleine molecules te bestuderen. In deze thesis werd aangetoond dat 
microsomen en S9 fracties geschikt zijn om potentiële peptide-metabolieten te identificeren. 
De resultaten zijn gelijkaardig aan reeds vroeger beschreven modellen, o.a. incubatie met 
vers serum[5]. Het voordeel van microsomen en S9-fracties ten opzichte van vers serum is de 
eenvoudige staalvoorbereiding, korte incubatietijden en weinig interferentie. Er werd geen 
significant verschil in metaboliet-vorming waargenomen tussen nier en lever-microsomen. 
Deamidatie werd met behulp van het deamiderende enzyme (α-chymotrypsin) onderzocht, 
omdat noch microsoom, S9 fracties , noch serum in staat zijn om peptides te deamideren. 
 
4 Detectie van kleine peptide-hormonen 
 
De verzamelde kennis beschreven in de voorgaande hoofdstukken over desmopressin 
(hoofdstuk 3 en 4), illegale preparaten (Hoofdstuk 5-8) en peptide-metabolisme (Hoofdstuk 
9) leidde tot de ontwikkeling van een UHPLC-HRMS detectiemethode om kleine peptide-
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hormonen in urine te detecteren in het kader van dopinganalyse. Dit wordt beschreven in  
hoofdstuk 10.  
De staalvoorbereiding bestond uit een zwakke kationen-uitwisseling vaste fase extractie[6,7]. 
Slechts 1 mL urine was nodig voor de extractie. De detectie werd uitgevoerd mbv een 
UHPLC-HRMS systeem (Orbitrap® Q-Exactive) in overeenstemming met het werk beschreven 
door Thomas et al.[6] in 2012.  Alle peptides werden gedetecteerd in positieve ionisatie 
modus (SIM). Voor elk peptide werd 1 geprotoneerd moleculair ion gemonitord. In totaal 
werden 31 substanties (waarvan 11 metabolieten) aan de methode toegevoegd. Drie 
verschillende inwendige standaarden werden gebruikt. De validatie toonde aan dat alle 
substanties tussen 20 en 500 pg/mL kunnen gedetecteerd worden. 
 
5 Algemeen besluit 
 
Deze thesis beschrijft de implementatie van de detectie van peptide-hormonen in het 
dopingcontrolelaboratorium van de Universiteit Gent. 
Dit onderzoek omvatte niet enkel de implementatie van het routinematig opsporen van 
peptide-hormonen maar ook het  karakteriseren en identificieren van nieuwe peptide-
hormonen. 
DoCoLab zal de in het kader van deze thesis ontwikkelde methode verder optimaliseren. 
Aangezien peptide-hormonen doorgaans in lage dosissen worden toegediend en ze snel 
gemetaboliseerd worden is “gevoeligheidsverbetering van de detectiemethodes” een 
belangrijk onderzoekspunt.  
Gevoeligere methodes kunnen vooral bekomen worden door technologische vooruitgang die 
ons betere massaspectrometers levert. Daarnaast kan een selectievere staalvoorbereiding of 
de identificatie van metabolieten die lang in het lichaam aanwezig blijven ook een 
substantiële verbetering in de detectie toelaten. Deze potentiële verbeteringen zullen ook 
de economische rentabiliteit van deze detectiemethodes ten goede komen. 
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Sinds de publicatie van de eerste detectie-methode, die de detectie van slechts een klein 
peptide bescheef (LHRH), in 2008[8] , werd er heel wat vooruitgang geboekt in de detectie 
van de peptide-hormonen. Deze vooruitgang is te danken aan het wetenschappelijk 
onderzoek in de verschillende WADA-laboratoria. Door dit onderzoek beschikken 
dopinglaboratoria momenteel over algemene procedures voor de ontwikkeling van 
detectiemethodes, uitvoeren van metabole studies en de identificatie van nieuwe peptide-
hormonen. Deze algemene procedures laten toe dat alle 32 geaccrediteerde laboratoria in 
de volgende jaren peptide-detectie-methodes implementeren. Om de implementatie van 
deze methodes in alle laboratoria op dezelfde manier te laten verlopen is er  nood aan 
harmonisatie. In het bijzonder ontbreken er voor verschillende peptides referentie-
standaarden en zijn er nog geen minimum required reporting levels (MRPL). In deze 
harmonisatie dient WADA een voortrekkersrol te nemen.   
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